

<教科書>

**Book**

1. 平川晃弘. 臨床試験方法論, 2025, メディカル・サイエンス・インターナショナル
2. **Hirakawa A**, Sato H, Daimon T, Matsui S. *Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted*, 2018, Springer.
3. Daimon T, **Hirakawa A**, Matsui S. *Dose-Finding Designs for Early Phase Cancer Clinical Trials*, 2019, Springer.

**Book chapter**

4. **Hirakawa A**, Matsui S. Dose-finding for two-agent combination phase I trials. *Developments in Statistical Evaluation of Clinical Trials*, 2014, Springer.
5. Daimon T, **Hirakawa A**, Matsui S. Phase I dose-finding designs and their applicability to targeted therapies, *Design and Analysis of Clinical Trials for Predictive Medicine*, 2014, CRC Press.
6. **Hirakawa A**, Sato H. A comparative study of model-based dose-finding methods for two-agent combination trials, *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*, 2017, Springer.
7. 前田圭介 (編著). 室谷健太 (編著). 生存時間データの分析. *臨床研究アウトプット術*, 2020, 中外医学社
8. 平川晃弘, 佐藤宏征. 臨床試験のデザインと統計解析. 内田一郎, 芹生卓 (編集). 製薬医学入門: くすりの価値最大化をめざして. 2022, メディカル・サイエンス・インターナショナル
9. 平川晃弘, マスタープロトコルに基づく臨床試験. 丹後 俊郎・松井 茂之 (編). 臨床試験の事典. 2023, 朝倉書店.

**翻訳**

10. 五所正彦 (監訳). 佐藤泰憲, 竹内久朗, 長島健悟, 中水流嘉臣, 平川晃弘 (共訳), 松永信人, 山田雅之. 生存時間解析入門 [原著第 2 版]. デビッド・ホスマー, スタンリー・レメショウ, スーザン・メイ *Applied Survival Analysis*, 2<sup>nd</sup> edition. 2014. 東京大学出版会.
11. 西山毅 (監訳). 菱田朝陽, 中枏昌弘, 室谷健太, 平川晃弘 (共訳). 実践でわかる! R による統計遺伝学. Andrea S. Foulkes. 2016. 丸善出版.
12. 平川晃弘 (監訳). 浅野淳一, 上村鋼平, 佐藤宏征, 木下文恵, 武内亜希子 (共訳). 臨床試験のためのデータモニタリング委員会: 実践ハンドブック. スーザン・エレンバーグ, トーマス・フレミング, デビット・デメッツ. *Data Monitoring Committees in Clinical Trials: A Practical Perspective*. 2017. サイエンティスト社.

13. 平川晃弘, 五所正彦 (監訳). 臨床試験のためのアダプティブデザイン. 2018. 朝倉書店.

<査読付論文>

**Biostatistics and Data Science**

1. Hanazawa R, Sato H, Suzuki K, Hirakawa A. Applying a Statistical Model-based AI Method to Identify Prognostic Factors for Long-Term Cognitive Decline in Alzheimer's Disease: Evidence from Pooled Placebo Data of Four Phase III Trials. *International Journal of Medical Informatics*, 2026 Feb 3;211:106337. doi: 10.1016/j.ijmedinf.2026.106337, 2026
2. Asano J, Sato H, Watanabe S, Hirakawa A. Bayesian power prior in platform trials with non-concurrent control for binary outcomes: development and comparative evaluation. *Statistics in Medicine*, 2026 Jan;45(1-2):e70387. doi: 10.1002/sim.70387. 2026.
3. Fukuokaya W, Mori K, Yanagisawa T, Ito K, Urabe F, Rajwa P, Shariat S F, Kimura T, Hirakawa A. Heterogeneity in treatment effects of reduced versus standard dose of cabazitaxel in metastatic castration-resistant prostate cancer. *Cancer Medicine*, 2026 Jan;15(1):e71507. doi: 10.1002/cam4.71507. 2026
4. Kitabayashi R, Takeda K, Sato H, Hirakawa A. BOIN-MEM: A two-stage design for dose optimization with information borrowing across dose levels and stages in oncology phase I/II trials. *Pharmaceutical Statistics*, 2025 Nov-Dec;24(6):e70045. doi: 10.1002/pst.70045.2025
5. Fukuokaya W, Mori K, Yanagisawa T, Urabe F, Rajwa P, Briganti A, Shariat S.F, Matsubara N, Kimura T, Hirakawa A. Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer. *Cancer*, 2025 Apr 1;131(7):e35819. doi: 10.1002/cncr.35819, 2025
6. Shimizu Y, Hanazawa R, Sato H, Hirakawa A. Operating characteristics of unequal allocation ratios in platform trials with the staggered addition of drugs using binary endpoints. *Contemporary Clinical Trial Communications*, 2025 Feb 17;44:101450. doi: 10.1016/j.conctc.2025.101450, 2025
7. Sato H, Hanazawa R, Suzuki K, Hashizume A, Hirakawa A. Self-Organized Prediction-Classification-Superposition of Longitudinal Cognitive Decline in Alzheimer's Disease: An Application to Novel Clinical Research Methodology. *IEEE Journal of Biomedical and Health Informatics*, 2025 Aug;29(8):5922-5935. doi: 10.1109/JBHI.2025.3546020, 2025
8. Kitabayashi R, Sato H, Nomura S, Hirakawa A. Bayesian Hierarchical Model with Adaptive Similarity Evaluation of Treatment Effects in Oncology Basket Trials. *Statistics in Biopharmaceutical Research*, <https://doi.org/10.1080/19466315.2025.2455562>, 2025
9. Takeda K, Zhu J, Hirakawa A. BF-BOIN-ET: A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose Optimization. *Pharmaceutical Statistics*, 2025 Mar-

- Apr;24(2):e2470. doi: 10.1002/pst.2470, 2025
10. [Hirakawa A](#), Asakawa T, Tokushige K, Ozaki R, Yoshida M, Sumiyoshi Okuma H, Saito S, Shimizu Y, Kitabayashi R, Hanazawa R, Sato H, Uemura Y. Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline. *Clinical Pharmacology & Therapeutics*, 2025 Mar;117(3):627-632. doi: 10.1002/cpt.3508, 2025.
  11. Hanazawa R, Sato H, [Hirakawa A](#), Alzheimer's Disease Neuroimaging Initiative. Mixture Disease Progression Model to Predict and Cluster the Long-Term Trajectory of Cognitive Decline in Alzheimer's Disease. *Therapeutic Innovation & Regulatory Science*, 2025 Mar;59(2):264-277. doi: 10.1007/s43441-024-00708-4, 2025
  12. Sasaki M, Sato H, Uemura Y, Mikami A, Ichihara N, Fujitani S, Kondo M, Doi Y, Morino E, Tokita D, Ohmagari N, Sugiura W, [Hirakawa A](#). How much more efficient are adaptive platform trials than multiple stand-alone trials? a comprehensive simulation study for streamlining drug development during a pandemic. *Clinical Pharmacology & Therapeutics*, 2024 Jun;115(6):1372-1382, doi: 10.1002/cpt.3224, 2024
  13. Sadachi R, Sato H, Fujiwara T, [Hirakawa A](#). Enhancement of Bayesian optimal interval design by accounting for overdose and underdose errors trade-offs. *Journal of Biopharmaceutical Statistics*, 2023 Nov 15:1-20, doi: 10.1080/10543406.2023.2275766, 2023
  14. Mizusawa J, Sato H, Rubinstein L V, Fujiwara T, Yonemori K, [Hirakawa A](#). Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials. *Cancer Medicine*, 00:1-12,doi: 10.1002/cam4.6370, 2023
  15. Hanazawa R, Sato H, Sasaki M, Suzuki K, [Hirakawa A](#). Study designs and statistical analyses in randomized controlled trials of non-pharmacological preventive and therapeutic interventions for dementia continuum : A statistical review. *Dementia Japan*,37(1):96-132, 2023
  16. Asano J, Sato H, [Hirakawa A](#). Practical basket design for binary outcomes with control of family-wise error rate. *BMC Medical Research Methodology*. 23 (1):52, doi: 10.1186/s12874-023-01872-1, 2023
  17. [Hirakawa A](#), Sato H, Hanazawa R, Suzuki K; Japanese Alzheimer's Disease Neuroimaging Initiative. Estimating the longitudinal trajectory of cognitive function measurement using short-term data with different disease stages: Application in Alzheimer's disease. *Statistics in Medicine*. 41(21):4200-4214, doi: 10.1002/sim.9504. 2022.
  18. [Hirakawa A](#), Sato H, Igeta M, Fujikawa K, Daimon T, Teramukai S. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. *Pharmaceutical Statistics*, 21: 691-695, 2022.
  19. Kawatsu Y, Tsuchida J, Ando S, [Hirakawa A](#), Sozu T. Sample size determination in phase I oncology trials based on selection probability of the maximum tolerated dose. *Japanese Journal of Biometrics*, 42(1) 55-64, doi: 10.5691/jjb.42.55, 2021.

20. Kaneko S, Hirakawa A (corresponding author). Assessment of overall treatment effect in the presence of inconsistent regional effects in multiregional clinical trials. *Statistics in Biopharmaceutical Research*. 13:219-229, doi:10.1080/19466315.2021.1845233,2020, (1.452)
21. Asano J, Hirakawa A (corresponding author). A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. *Pharmaceutical Statistics* 2020 19(6):975-1000,2020
22. Kaneko S, Hirakawa A, Kakurai Y, Hamada C. A dose-finding approach for genomic patterns in phase I trials. *Journal of Biopharmaceutical Statistics*. 2;30(5):834-853, doi: 10.1080/10543406.2020.1744619, 2020.
23. Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma SH, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. *Clinical Pharmacology & Therapeutics*. 106:803-809, 2019.
24. ※Kakurai Y, Kaneko S, Hamada C, Hirakawa A (corresponding author). Dose individualization and variable selection using Bayesian Lasso in early phase dose-finding trials. *Applied Statistics*. 68:445-460, 2019.
25. Kada A, Hirakawa A (co-first author), Kinoshita F, Kobayashi Y, Hatakeyama T, Kobayashi D, Nishiyama C, Iwami T. Sample size estimation and re-estimation of cluster randomized controlled trials for real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests. *Contemporary Clinical Trials Communications*. 14: 100316, 2019.
26. Hirakawa A, Tanaka Y, Kaneko S. Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials. *Contemporary Clinical Trial Communications*. <https://doi.org/10.1016/j.conctc.2019.100489>, 2019.
27. Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. *Contemporary Clinical Trial Communications*, 12:1-8, 2018.
28. Hirakawa A, Hatakeyama T, Kobayashi D, Nishiyama C, Kada A, Kiguchi T, Kawamura T, Iwami T. Real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests: study protocol for a randomized controlled trial. *Trials*. 19 :510, 2018.
29. ※Shimamura F, Hamada C, Matsui S, Hirakawa A (corresponding author). Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials. *Journal of Biopharmaceutical Statistics*, 18:1-13, 2018.
30. Hirakawa A, Yonemori K, Kinoshita F, Kobayashi Y, Okuma H, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trial. *Cancer Science*, 109:207-

214, 2018.

31. [Hirakawa A](#), Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, Ueda T, Ozaki T, Tamura K, Kawai A, Fujiwara Y. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: a case study of phase 2 trial for sarcoma. *Therapeutic Innovation & Regulatory Science*, 52:334-338, 2018.
32. Nomura S, [Hirakawa A](#), Hamada C. Sample size determination for the current strategy in oncology phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework. *Journal of Biopharmaceutical Statistics*, 8: 1-23, 2017.
33. Goshō M, Maruo K, Tada K, [Hirakawa A](#). Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. *European Journal of Clinical Pharmacology*, 73: 779-786, 2017.
34. Shimura M, Goshō M, [Hirakawa A](#). Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data. *Statistics in Medicine*, 36:2067-2080, 2017.
35. [Hirakawa A](#), Kinoshita F. An analysis of Japanese patients enrolled into multiregional clinical trials in oncology. *Therapeutic Innovation & Regulatory Science*, 51: 207–211, 2017.
36. Asano J, [Hirakawa A \(co-first author\)](#). Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: application to breast cancer data. *Journal of Biopharmaceutical Statistics*, 1-15, doi: 10.1080/10543406.2017.1293082, 2017 Feb 13.
37. Goshō M, Maruo K, Ishii R, [Hirakawa A](#). Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation. *Statistical Methods in Medical Research*, DOI: 10.1177/0962280216677879, 2016.
38. [Hirakawa A](#), Sato H, Goshō M. Effect of design specifications in dose-finding trials for combination therapies in oncology. *Pharmaceutical Statistics*, 15: 531-540, 2016.
39. Sato H, [Hirakawa A \(co-first author\)](#), Hamada C. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. *Statistics in Medicine*, 35:4093-4109, 2016.
40. Yonemori K, [Hirakawa A \(co-first author\)](#), Kawachi A, Kinoshita F, Ohkuma H, Nishikawa T, Kenji T, Fujiwara Y, Takebe N. Drug induced Interstitial Lung Disease in Oncology Phase I Trials. *Cancer Science*, 107(12):1830-1836, 2016.
41. [Hirakawa A](#), Sato H. Authors' Reply: Response to Letter to the Editor by Drs Riviere et al. *Statistics in Medicine*, 35: 479-480, 2016.
42. Goshō M, [Hirakawa A](#), Maruo K, Noma H, Sato Y. Comparison of bias-corrected covariance estimators for MMRM analysis in longitudinal data with dropouts. *Statistical Method in Medical Research*, doi: 10.1177/0962280215597938, 2015.
43. [Hirakawa A](#), Wages NA, Sato H, Matsui S. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. *Statistics in Medicine*, 34: 3194-3213, 2015.

44. Hirakawa A and Matsui S. Operating characteristics of restrictions on skipping dose level for adaptive dose-finding method in two-agent phase I trials. *Japanese Journal of Biometrics*, 36:1-12, 2015.
45. Kakurai Y, Hirakawa A, Hamada C. A dose-finding method based on multiple dosing in two-agent combination phase I trials. *Journal of Biopharmaceutical Statistics*, 25:1065-1076, 2015.
46. Kaneko S, Hirakawa A, Hamada C. Enhancing the lasso approach for developing a survival prediction model based on gene expression data. *Computational and Mathematical Methods in Medicine*, 2015: 259474, 2015.
47. Hirakawa A, Yonemori K, Kuwatsuka Y, Kodaira M, Yamamoto H, Yunokawa M, Hamada A, Shimizu C, Tamura K, Gemma A, Fujiwara Y. A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan. *Current Drug Safety*, 9: 220-226, 2014.
48. Asakawa T, Hirakawa A, Hamada C. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials. *Journal of Biopharmaceutical Statistics*, 23:310-325, 2014.
49. Asano J, Hirakawa A, Hamada C. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer data. *Pharmaceutical Statistics*, 13:357-363, 2014.
50. Hirakawa A, Matsui S. Response to Letter to the Editor by Drs Wages et al. *Statistics in Medicine*, 33:2159-60 2014.
51. Asano J, Hirakawa A, Hamada C. A stepwise variable selection for a Cox proportional hazards cure model with application to breast cancer data. *Japanese Journal of Biometrics*, 34: 21-34, 2013.
52. Hirakawa A, Hamada C, Matsui S. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. *Statistics in Medicine*, 32:4515-4525,2013
53. Hirakawa A. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. *Statistics in Medicine*, 31:516-532, 2012.
54. Kaneko S, Hirakawa A, Hamada C. Gene selection using a high-dimensional regression model with microarrays with cancer prognostic studies. *Cancer Informatics*, 11: 29-39, 2012.
55. Hirakawa A, Hamada C, Yoshimura I. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. *Journal of Biopharmaceutical Statistics*, 22:260-275, 2012.
56. Hirakawa A, Hamada C, Yoshimura I. Sample size calculation for a regularized t-statistic in microarray experiments. *Statistics and Probability Letters*, 81:870-875, 2011.
57. Ando Y, Hirakawa A. Discussion of “Adaptive and Model-Based Dose-Ranging Trials:

Quantitative Evaluation and Recommendations". *Statistics in Biopharmaceutical Research*, 2: 462-465, 2010.

58. Ando Y, [Hirakawa A](#), Uyama Y. Adaptive clinical trials for new drug applications in Japan. *European Neuropsychopharmacology*, 21: 175-179, 2010.
59. [Hirakawa A](#), Sato Y, Hamada C, Yoshimura I. A new test statistic based on shrunken sample variance for identifying differentially expressed genes in small microarray experiments. *Bioinformatics and Biology Insights*, 2:145-156, 2008.
60. [Hirakawa A](#), Sato Y, Sozu T, Hamada C, Yoshimura I. Estimating the false discovery rate using mixed normal distribution for identifying differentially expressed genes in microarray data analysis. *Cancer Informatics*, 3:367-375, 2007.

### **Cooperative Clinical and Basic Researches**

61. Tanabe K, Yoshida S, Chen W, Yajima S, Sato H, [Hirakawa A](#), Fukushima H, Yasuda Y, Tanaka H, Masuda H, Fujii Y. Bayesian Multi-criteria Decision Analysis of Net Clinical Benefit in ARASENS: Overall and Japanese Subgroup Results. *International Journal of Urology*, 2026 Feb;33(2):e70384. doi: 10.1111/iju.70384. 2026
62. Fukushima H, Yajima H, Sato H, [Hirakawa A](#), Yoshida S, Fujii Y. Bayesian re-interpretation of the CheckMate-9ER final analysis: organ-site and IMDC risk-stratified probabilities of benefit. *International Journal of Urology*, 2026 Feb;33(2):e70379. doi: 10.1111/iju.70379.2026
63. Chen W, Yoshida S, Yajima S, Tanabe K, Fujiwara M, Fukushima H, Tanaka H, [Hirakawa A](#), Masuda H, Fujii Y. Delayed survival benefit of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: a time-dependent analysis of reconstructed individual patient data from the PEACE-3 trial. *International Journal of Urology*, 2026 Feb;33(2):e70376. doi: 10.1111/iju.70376. 2026
64. Matsuura K, Yoshimura H, Tsukahara Y, [Hirakawa A](#), Hanazawa R, Takumi Y. Evaluation of Growth and Development of the External Auditory Canal Using 624 Temporal Bone CT Scans for Appropriate Cochlear Gene Delivery. *Otology & Neurotology*, 2026 Feb 16. doi: 10.1097/MAO.0000000000004864. 2026.
65. Fukuokaya W, Mori K, Yanagisawa T, Ito K, Urabe F, Rajwa P, Shariat S F, Kimura T, [Hirakawa A](#). Heterogeneity in treatment effects of reduced versus standard dose of cabazitaxel in metastatic castration-resistant prostate cancer. *Cancer Medicine*, 2026 Jan;15(1):e71507. doi: 10.1002/cam4.71507. 2026
66. Fukushima H, Yoshida S, Yajima S, Chen W, Sato H, [Hirakawa A](#), Fujiwara M, Arita Y, Yasuda Y, Tanaka H, Morizane S, Yokoyama M, Masuda H, Takenaka A, Fujii Y. A Multi-Criteria Decision Analysis Comparing Robot-Assisted, Laparoscopic, and Open Radical Cystectomy Using Large-Scale Japanese Nationwide Databases. *Journal of Robotic Surgery*, 2026 Feb

- 10;20(1):230. doi: 10.1007/s11701-026-03201-2. 2026
67. Yajima S, Chen W, Hirose K, Hirakawa A, Tanabe K, Fujiwara M, Fukushima H, Tanaka H, Masuda H, Fujii Y, Yoshida S. Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis. *European Urology Open Science*, 2026 Feb 6:85:60-70. doi: 10.1016/j.euros.2026.01.013. 2026
  68. Yajima S, Yoshida S, Chen W, Sato H, Hirakawa A, Fukushima H, Nakamura Y, Tanaka H, Inoue M, Numao N, Yoshinaga A, Kawamura N, Yonose I, Izumi K., Yamamoto T, Uehara S, Suzuki K, Toide M, Takazawa R, Araki S, Masuda H, Fujii Y. Real-World Efficacy of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma Stratified by EV-301 Trial Eligibility: A Multicenter Bayesian Restricted Mean Survival Time Analysis. *Japanese Journal of Clinical Oncology*, 2026 Jan 28:hyag012. doi: 10.1093/jjco/hyag012. 2026
  69. Tanabe K, Yoshida S, Chen A, Yajima S, Hirakawa A, Fujii Y. Non-proportional hazards analysis of the RADIOSA trial using reconstructed individual patient data. *International Journal of Urology*, 2026 Jan;33(1):e70354. doi: 10.1111/iju.70354. 2026
  70. Ooka J, Miyazaki S, Nitta J, Nakamura K, Kobori A, Inaba O, Murakami M, Yamauchi Y, Sekiguchi Y, Sasaki T, Sasaki Y, Inamura Y, Mizuno S, Sagawa Y, Asano S, Naito S, Ohya H, Hirakawa A, Sasano T. Predictors of Arrhythmia Recurrence After Cryoballoon Ablation in Paroxysmal Atrial Fibrillation: A Comparative Analysis from the CONTRAST-CRYO Trial. *Journal of Interventional Cardiac Electrophysiology*, 2026 Jan 16. doi: 10.1007/s10840-026-02240-x. 2026
  71. Chen W, Yoshida S, Yajima S, Sato H, Hirakawa A, Fujii Y. Quantifying benefit of adding docetaxel to androgen receptor-axis therapy in metastatic hormone-sensitive prostate cancer with Bayesian analysis. *International Urology and Nephrology*, 2026 Jan 4. doi: 10.1007/s11255-026-04998-5. 2026
  72. Fukushima H, Yajima S, Chen W, Hirakawa A, Tanabe K, Fujiwara M, Arita Y, Tanaka H, Masuda H, Fujii Y, Yoshida S. Time-dependent comparative effectiveness of first-line treatment for metastatic clear cell renal cell carcinoma: a restricted mean survival time-based network meta-analysis. *Targeted Oncology*, 2026 Jan;21(1):1-12. doi: 10.1007/s11523-025-01194-w. 2026
  73. Chen W, Yoshida S, Yajima S, Sato H, Hirakawa A, Tanabe K, Fukushima H, Yasuda Y, Tanaka H, Masuda H, Fujii Y. Pharmacologic synergy versus independent action in androgen receptor-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysis. *Urologic Oncology*, 2026 Jan 21;44(4):110990. doi: 10.1016/j.urolonc.2025.110990. 2025
  74. Hirose K, Yoshida S, Chen W, Yajima S, Hirakawa A, Tanabe K, Fujiwara M, Fukushima H, Yasuda Y, Tanaka H, Masuda H, Fujii Y. Bayesian reanalysis to assess consistency of TALAPRO-2 results in the Japanese subgroup with metastatic castration-resistant prostate cancer.

- Japanese Journal of Clinical Oncology*, 2026 Jan 16;hyaf219. doi: 10.1093/jjco/hyaf219. 2026
75. Yajima S, Yoshida S, Chen W, Sato H, Hirakawa A, Fujiwara M, Yokoyama M, Arita Y, Fukushima H, Yasuda Y, Tanaka H, Masuda H, Fujii Y. Probabilistic Multi-criteria Decision Analysis Comparing Robot-Assisted and Laparoscopic Radical Nephroureterectomy. *Journal of Robotics Surgery*, 2026 Jan 9;20(1):162. doi: 10.1007/s11701-025-03124-4. 2026
  76. Soma T, Tanaka H, Nakamura Y, Numao N, Inoue M, Yoshinaga A, Kawamura N, Tanabe K, Izumi K, Yamamoto T, Uehara S, Maezawa Y, Toide M, Takazawa R, Araki S, Kitabayashi R, Hirakawa A, Yoshida S, Koga F, Fujii Y. Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study). *International Journal of Urology*, 2026 Jan;33(1):e70329. doi: 10.1111/iju.70329. 2026
  77. Chen W, Yoshida S, Hirakawa A, Sato H, Yajima S, Kobayashi M, Fujiwara M, Fukushima H, Arita Y, Waseda Y, Tanaka H, Masuda H, Fujii Y. Clinical efficacy of apalutamide in Asian patients with metastatic castration-sensitive prostate cancer: Bayesian reanalysis of the TITAN trial. *Japanese Journal of Clinical Oncology*, 2025 Dec 26;hyaf206. doi: 10.1093/jjco/hyaf206. 2025
  78. Yasuda Y, Yoshida S, Yajima S, Sato H, Hirakawa A, Fujii Y. Restricted mean survival time comparison of olaparib plus abiraterone versus talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer: indirect analyses of propel and talapro-2. *International Urology and Nephrology*, 2025 Dec 19. doi: 10.1007/s11255-025-04951-y. 2025
  79. Hashizume A, Hanazawa R, Yamada S, Ito D, Kishimoto Y, Komori S, Kawase T, Iida M, Kondo A, Mori Y, Obara K, Morita M, Yamamoto T, Sato H, Hirakawa A, Katsuno M. Therapeutic impact of leuprorelin acetate on spinal and bulbar muscular atrophy Pre- and post-marketing observational study. *Journal of Neurology*, 2025 Nov 19;272(12):772. doi: 10.1007/s00415-025-13509-y. 2025
  80. Suzuki K, Endo A, Akutsu T, Hoshi H, Suekane A, Yamamoto R, Yamakawa K, Watanabe S, Hirakawa A, Otomo Y, Morishita K. Seasonal and cultural effects on calendar day variations in trauma incidence in Japan. *Scientific Reports*, 2025 Dec 18;15(1):44106. doi: 10.1038/s41598-025-27973-z. 2025
  81. Takahashi T, Sato H, Takahashi Y, Watanabe K, Bannno T, Sakaki K, Arai Y, Takano Y, Eguchi Y, Taniguchi Y, Maki S, Aoki Y, Yoshii T, Yamada H, Kaito T, Hiraizumi Y, Yamagata M, Nakamura M, Hosogane N, Hirakawa A, Ohtori S, Hirai T. Cost-Effectiveness of Intradiscal Injection with Condoliase versus Microendoscopic Discectomy for Lumbar Disc Herniation: A Retrospective Multicenter Study. *Scientific Reports*, 2025 Dec 16;15(1):43913. doi: 10.1038/s41598-025-27802-3. 2025
  82. Nankaku A, Kasai S, Shiomi A, Masuda T, Hazama H, Iwata N, Kato S, Yamauchi S, Sato H,

- Hirakawa A, Kagawa H, Tokunaga M, Kinugasa Y. Comparing prophylactic administration of sulbactam/ampicillin versus cefmetazole for prevention of perineal wound infection following abdominoperineal resection for rectal cancer: A multicenter randomized controlled trial. *Annals of Gastroenterological Surgery*, 2025 Oct 26;10(1):15-24. doi: 10.1002/ags3.70118. 2025
83. Yajima S, Yoshida S, Chen W, Hirose K, Hirakawa A, Tanabe K, Fujiwara M, Fukushima H, Tanaka H, Masuda H, Fujii Y. Bayesian Reanalysis of Avelumab Maintenance Therapy in Asian and Japanese Patients with Advanced Urothelial Carcinoma: Evidence from the JAVELIN Bladder 100 Trial. *Japanese Journal of Clinical Oncology*, 2026 Feb 13;56(2):216-220. doi: 10.1093/jjco/hyaf166. 2025
84. Yajima S, Yoshida S, Fukushima H, Hirakawa A, Masuda H, Fujii Y. Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial. *International Journal of Urology*, 2026 Jan;33(1):e70256. doi: 10.1111/iju.70256. 2025
85. Yamamoto T, Takahashi Y, Takagi S, Kitabayashi R, Ishii S, Sugihara G, Oyama J, Miyazaki S, Goya M, Hirakawa A, Takahashi H, Sasano T. Neurocognitive Function, Cerebral Blood Flow and Hippocampal Volume after Catheter Ablation of Atrial Fibrillation. *JACC Clinical Electrophysiology*, 2026 Feb 3:S2405-500X(26)00001-0. doi: 10.1016/j.jacep.2025.12.037. 2026
86. Tateishi R, Miyazaki S, Yamao K, Negishi M, Honda M, Omori M, Kanno Y, Kawamura I, Matsuda Y, Yamakami Y, Goto K, Hirasawa K, Nishimura T, Ochida M, Sugiyama T, Tao S, Umemoto T, Takigawa M, Yonetsu T, Maejima Y, Hirakawa A, Sasano T. Evaluation of Continuous Arrhythmia Monitoring Using an Implantable Loop Recorder in Heart Failure Patients with a Reduced Ejection Fraction: The LINQ2-HF trial rationale and protocol. *PLOS ONE*, 2025 Aug 28;20(8):e0321604. doi: 10.1371/journal.pone.0321604. 2025
87. M.D.Maeda T, Sato Y, Hirakawa A, Nakatochi M, Kinoshita F, Suzuki T, Ichimura S, Kidokoro H, Kawada J, Takahashi Y, Nagoya University Collaborative Clinical Research Team. Gastric Lavage for Neonates with Coffee-Ground Hematemesis in Early Postnatal Period: Randomized Controlled Trial. *Pediatrics & Neonatology*, 2025 Nov 1:S1875-9572(25)00194-9. doi: 10.1016/j.pedneo.2025.05.014. 2025
88. Nakatochi M, Yoshida K, Fujitani M, Ohashi Y, Kinoshita F, Kobayashi Y, Sato H, Takahashi Y, Murashita K, Hirakawa A. Associations among smoking, sleep quality, and decline in Mini-Mental State Examination scores based on health check-up data in Japan: a case-control study. *Nagoya journal of medical science*, 2025 Feb;87(1):105-121, doi: 10.18999/nagjms.87.1.105, 2025
89. Osuga Y, Kobayashi T, Hirakawa A, Takayanagi T, Nogami M, Tayzar K, Mochiyama T,

- Hirayama M, Foidart J.-M, Harada T. Efficacy and safety of estetrol (15 mg)/drospirenone (3 mg) combination in a cyclic regimen for the treatment of primary and secondary dysmenorrhea: a multicenter, placebo-controlled, double-blind, randomized study. *Fertility and Sterility*, 2025 Apr;123(4):700-708. doi: 10.1016/j.fertnstert.2024.11.003. 2025
90. Takenaka K, Hisamatsu T, Kobayashi T, Yamamoto H, Ohmiya N, Hayashi R, Matsuoka K, Saruta M, Andoh A, Fukata N, Watanabe K, Imaeda H, Hirai F, Matsumoto T, Hirakawa A, Yano T, Matsuura M, Okamoto R, Ohtsuka K, Watanabe M. Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn's Disease; A Prospective Multicenter Study. *Clinical gastroenterology and hepatology*, 2025 Oct;23(11):1991-2000. doi: 10.1016/j.cgh.2024.10.030. 2025
  91. Sugimoto M, Kikuchi H, Sohara E, Mizutani K, Limbutara K, Hirakawa A, Mori T, Susa K, Oya S, Suzuki T, Naito S, Iimori S, Tatemitsu R, Fushimi K, Uchida S. Biguanides Associate with Decreased Early Mortality and Risk of Acute Kidney Injury In Hospitalized COVID-19 Patients: a nationwide retrospective cohort study in Japan. *Clinical and Experimental Nephrology*, 2026 Jan;30(1):33-44. doi: 10.1007/s10157-025-02755-z. 2025
  92. Hanaoka M, Kagawa H, Ishiguro M, Hirakawa A, Tokunaga M, Kinugasa Y. Long-term prognosis of intracorporeal versus extracorporeal anastomosis in stage II/III colorectal cancer (INEX study): study protocol for a multicenter randomized controlled trial in Japan. *BMC Cancer*, 2025 Jul 30;25(1):1242, doi:10.1186/s12885-025-14676-x, 2025
  93. Ouchi S, Yamada T, Shinohara T, Mabuchi S, Nakagawa K, Yoshimi K, Horike A, Mayama T, Toyoshima K, Tamura Y, Araki A, Hanazawa R, Hirakawa A, Ichige H, Ishida T, Kimura T, Tohara H, Hashimoto M. Association between Diaphragm Excursion and Whole-Body Muscle Mass in Older Adults: An Observational Study. *Scientific Reports*, 2025 Jul 3;15(1):23762. doi: 10.1038/s41598-025-08997-x, 2025
  94. Kobayashi M, Tanaka H, Hanazawa R, Nicaise E, Patil D, Meagher M, Nguyen M V, Fukuda S, Yoshida S, Saito K, Hirakawa A, Master V A, Derweesh I H, Fujii Y. Racial Disparities in Patient Survival and Clinical Features of Recurrence After Surgery for Non-Metastatic Renal Cell Carcinoma: An International Multicenter Study. *JU Open Plus*, 3(8):e00093, August 2025, doi: 10.1097/JU9.0000000000000329, 2025
  95. Miyazaki S, Nitta J, Nakamura K, Kobori A, Inaba O, Murakami M, Yamauchi Y, Sekiguchi Y, Sasaki T, Sasaki Y, Inamura Y, Mizuno S, Sagawa Y, Asano S, Naito S, Ooka J, Ohya H, Nishimura T, Hirakawa A, Sasano T. Two Different Cryoballoon Systems for Treatment of Paroxysmal Atrial Fibrillation: Results From the CONTRAST-CRYO Trial. *Circulation: Arrhythmia and Electrophysiology*, <https://doi.org/10.1161/CIRCEP.125.014041>, 2025
  96. Kurita T, Okamoto K, Sekiya N, Hanazawa R, Yamamoto A, Hosoya T, Hirakawa A, Yasuda S, Gu Y. Proposed Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Patients with

- Autoimmune Inflammatory Rheumatic Diseases: A Proof-of-Concept Study. *Journal of Fungi*, 2025 Jun 7;11(6):437. doi: 10.3390/jof11060437, 2025
97. Aoyama Y, Uchiyama C, Koike Y, Hayashi K, Tokuda I, Sato H, Hirakawa A, Yamamoto Y, Kobayashi W, Ihara K, Murashita K, Nakaji S. Association between Salivary pH and Estimated Glomerular Filtration Rate Status in a Community-Dwelling Population: A Cross-Sectional Study. *Nephron*, 2025 May 20;1-11. doi: 10.1159/000546401, 2025.
  98. Kodama Y, Nishi M, Sato A, Imamura C, Deguchi T, Hirakawa A, Kiyokawa N, Ohki K, Shima H, Kato K, Kato M, Kawasaki H, Sakaguchi H, Hiramatsu H, Goto H, Yamamoto S, Ito M, Tanizawa A, Yuza Y, Saito M A, Ogawa C, Taga T, Adachi S, Shimada H. A prospective study evaluating the safety and pharmacokinetics of ponatinib at a fixed dose in six paediatric patients with philadelphia chromosome-positive leukaemia: JCCG PedPona19 study. *British Journal of Haematology*, Letter2025 Jul;207(1):308-311, doi: 10.1111/bjh.20146, 2025
  99. Sagawa H, Sakakura Y, Hanazawa R, Takahashi S, Wakabayashi H, Fujii S, Fujita K, Hirai S, Hirakawa A, Kono K, Sumita K. Novel artificial intelligence approach in neurointerventional practice: Preliminary findings on filter movement and ischemic lesions in carotid artery stenting. *Clinical Neurology and Neurosurgery*,2025 Jul:254:108930, doi: 10.1016/j.clineuro.2025.108930, 2025
  100. Kato M, Sato H, Naito Y, Yamamoto A, Kawanishi H, Nakano Y, Nishikimi T, Kobayashi M, Kondo A, Hirabayashi H, Katsuno S, Sakamoto F, Kimura T, Yamamoto S, Araki H, Tochigi K, Ito F, Hatsuse H, Sassa N, Hirakawa A, Akamatsu S, Tsuzuki T. Prospective observational study on the relationships between genetic alterations and survival in Japanese patients with metastatic castration-sensitive prostate cancer: the impact of IDC-P. *International journal of clinical oncology*. 2025 30:789-796, doi:10.1007/s10147-025-02707-3, 2025
  101. Yamada T, Minami T, Shinohara T, Ouchi S, Mabuchi S, Yoshino S, Emoto K, Nakagawa K, Yoshimi K, Saito M, Horike A, Toyoshima K, Tamura Y, Araki A, Hanazawa R, Hirakawa A, Ishida T, Kimura T, Tohara H, Hashimoto M. The Impact of Ageing on Diaphragm Function and Maximal Inspiratory Pressure: A Cross-Sectional Ultrasound Study. *Diagnostics*, 2025 Jan 13;15(2):163, doi: 10.3390/diagnostics15020163, 2025
  102. Itakura T, Sasaki H, Hosoya T, Umezawa N, Saito T, Iwai H, Hasegawa H, Sato H, Hirakawa A, Imai K, Morio T, Kimura N, Yasuda S. The role of TRECs/KRECs as immune indicators that reflect immunophenotypes and predict the risk of infection in systemic autoimmune diseases. *Immunological Medicine*. 2025 Sep;48(3):233-244. doi: 10.1080/25785826.2025.2460275. Epub 2025 Feb 3. 2025
  103. Shinohara T, Yamada T, Ouchi S, Mabuchi S, Hanazawa R, Nakagawa K, Yoshimi K, Mayama T, Horike A, Toyoshima K, Tamura Y, Araki A, Tohara H, Hirakawa A, Kimura T, Ishida T, Hashimoto M. Relationship Between Diaphragm Function and Sarcopenia Assessed by

- Ultrasound: A Cross-Sectional Study. *Diagnostics*, 2025 Jan 3;15(1):90, doi: 10.3390/diagnostics15010090. 2025
104. Chen W, Tanaka H, Kobayashi M, Fukuda S, Nakayama A, Meagher F M, Yoshida S, Derweesh I H, Master V A, Hirakawa A, Fujii Y, Saito K. Racial disparity in preoperative C-reactive protein level for predicting prognosis of patients with non-metastatic clear cell renal cell carcinoma: INMARC study. *International Journal of Urology*, 2025 Apr;32(4):414-422, doi: 10.1111/iju.15671. 2025
105. Waseda Y, Chen W, Yokoyama M, Fukuda S, Tanaka H, Yoshida S, Ai M, Hirakawa A, Fushimi K, Fujii Y. Impact of surgical volume on outcomes of laparoscopic adrenalectomy for benign adrenal tumors: A Japanese nationwide database analysis. *International Journal of Urology*, 2025 Apr;32(4):409-413, doi: 10.1111/iju.15670. 2025
106. Kaga M, Sasaki M, Masuda T, Sato H, Ueda T, Hirakawa A. Exploring the association between happy hypoxia and Coronavirus disease 2019 in the triage phase. *Future Science OA*, 2025 Dec;11(1):2458413, doi: 10.1080/20565623.2025.2458413. 2025
107. Hirai T, Takahashi T, Takahashi Y, Watanabe K, Banno T, Sakaki K, Arai Y, Takano Y, Eguchi Y, Taniguchi Y, Maki S, Aoki Y, Fujii S, Sakaeda K, Matsukura Y, Akazawa T, Minamide A, Nojiri H, Sakai K, Kato S, Tamai K, Suzuki H, Miyagi M, Sato H, Yoshii T, Yamada H, Kaito T, Hiraizumi Y, Yamagata M, Nakamura M, Hirakawa A, Hosogane N, Ohtori S. Clinical and Economic Outcomes of Intradiscal Injection of Condoliase for a Treatment of Lumbar Disc Herniation with Severe Low Back Pain: A Multicenter Study. *Spine Surgery and Related Research*, 2024 Dec 20;9(3):368-374, doi: 10.22603/ssrr.2024-0288. 2024
108. Arai S, Hanaoka M, Yamauchi S, Baba H, Hanazawa R, Sato H, Hirakawa A, Tokunaga M, Kinugasa Y. Modified oral antibiotics and mechanical bowel preparation (OAMBP) versus conventional OAMBP for sigmoid colon and rectal surgery: A multicenter randomized non-inferiority trial. *Annals of Gastroenterological Surgery*, 2024 Jun 20;8(6):1036-1045, doi: 10.1002/ags3.12837. 2024
109. Harada T, Kobayashi T, Hirakawa A, Takayanagi T, Nogami M, Mochiyama T, Hirayama M, Foidart J-M, Osuga Y. Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study. *Fertility and Sterility*, 2024 Nov;122(5):894-901, doi: 10.1016/j.fertnstert.2024.07.011. 2024
110. Komatsuzaki K, Otani Y, Kageshima H, Sekino Y, Suzuki Y, Ugajin T, Tamaoka M, Yorozu P, Hanazawa R, Hirakawa A, Murakami D, Miyazaki Y. Safety of local nasal immunotherapy using hypoallergenic birch pollen ointment in patients with pollen-food allergy syndrome: A preliminary study of five cases. *Allergology International*, 2025 Apr;74(2):336-339. doi: 10.1016/j.alit.2024.10.006. 2025

111. Katsuda H, Kobayashi M, Ito G, Kawamoto A, Krimura S, Sato H, [Hirakawa A](#), Akahoshi K, Kudo A, Ohtsuka K, Okamoto R. Evaluating endoscopic ultrasound-guided tissue acquisition for diagnosis of small pancreatic neuroendocrine neoplasms. *Endoscopy International Open*, 2024 Nov 28;12(11):E1379-E1385. doi: 10.1055/a-2422-9363. 2024
112. Uemura Y, Yamamoto M, Ishimura M, Kanegane H, Sawada A, [Hirakawa A](#), Imadome K, Yoshimori M, Nagata M, Yamamoto K, Shimizu N, Koike R, Arai A. JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study. *Blood Neoplasia*, 2024 Nov 2;2(1):100053, doi: 10.1016/j.bneo.2024.100053. 2024
113. Sato Y, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Ando M, Tsuda K, Iwata O, Muramatsu Y, Kidokoro H, [Hirakawa A](#), Hayakawa M, SHEILD team. Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial). *STEM CELLS Translational Medicine*, 2024 Nov 12;13(11):1053-1066, doi: 10.1093/stcltm/szae071. 2024
114. Kawamura I, Miyazaki S, Inamura Y, Nitta J, Kobori A, Nakamura K, Murakami M, Nakamura T, Inaba O, Sekiguchi Y, Asano S, Sasaki Y, Mizuno S, Naito S, [Hirakawa A](#), Sasano T. A randomized controlled trial of the size-adjustable cryoballoon vs conventional cryoballoon for paroxysmal atrial fibrillation: The CONTRAST-CRYO II trial rationale and design. *Heart rhythm O2*, 5(5):301-306. doi: 10.1016/j.hroo.2024.04.006, 2024
115. Ikenouchi T, Miyazaki S, Nitta J, Sekiguchi Y, Kobori A, Nakamura K, Inamura Y, Murakami M, Sagawa Y, Sasaki Y, Inaba O, Yamauchi Y, Naito S, [Hirakawa A](#), Sasano T. Characteristics of two different cryoballoon systems for treatment of paroxysmal atrial fibrillation: study protocol for a multicenter randomized controlled trial (CONTRAST-CRYO Trial). *Journal of interventional cardiac electrophysiology*, 67(1):5-12. doi: 10.1007/s10840-023-01718-2, 2024
116. Mori N, Nanki T, [Hirakawa A](#), Yamato M, Kaneko Y, Shiokawa R, Ozaki R, Kawabata N, Ohmagari N. Tocilizumab in combination with standard of care in patients with severe COVID-19 pneumonia: efficacy and safety from a phase 3 clinical trial in Japan. *Journal of Infection and Chemotherapy*, S1341-321X(24)00265-4. doi: 10.1016/j.jiac.2024.09.013, 2024
117. Hirai S, Fujita K, Fujii S, Takahashi S, Shigeta K, Karakama J, Enomoto Y, Sato Y, Yoshimura M, Hirota S, Mizoue T, Yoshino Y, Kawano Y, Yamamura T, Kohyama S, Hirohata M, Yoshimura S, Ishii Y, Yamauchi T, Taira N, Obata Y, Sakamoto M, Inoue M, Yamashina M, Tokunaga S, Higashi T, Sawada K, Mochida H, Ido K, Takeuchi M, Takigawa T, Takagi Y, Morimoto M, Nanto M, Miki K, Misaki K, Arimura K, Hanaoka Y, Hara M, Hara S, Yokoyama K, Ooyama J, Hanazawa R, Sato H, [Hirakawa A](#), Ishiguro M, Nemoto S, Sumita K. Study protocol of the ASTOP trial: a multicenter, randomized, double-blind, placebo-controlled trial of presurgical aspirin administration for the prevention of thromboembolic complications of coil embolization for ruptured aneurysms. *PLOS ONE*, 19(9):e0310906. doi:

10.1371/journal.pone.0310906. eCollection 2024

118. Murofushi K, Katagiri H, Mitomo S, Hirohata K, Furuya H, Hanazawa R, [Hirakawa A](#), Yagishita K, Kaneoka K. Exploring Age-Related Changes in Motor Function: Insights from the Peak Decline Found in Koji Awareness Screening Test. *Scientific Reports*, 14(1):18903. doi: 10.1038/s41598-024-69971-7.2024
119. Tanaka H, Fukawa Y, Yamamoto K, Tanimoto K, Takemoto A, Mori T, Hasumi H, Kinoshita M, Kanazawa T, Furukawa A, Kimura K, Sato H, [Hirakawa A](#), Fukuda S, Waseda Y, Yoshida S, Campbell S C, Fujii Y. Prognostic impact and genomic backgrounds of renal parenchymal infiltration or micronodular spread in non-metastatic clear cell renal cell carcinoma. *Modern Pathology*, 37(11):100590. doi: 10.1016/j.modpat.2024.100590.2024
120. Ohara M, Hirata K, Matsubayashi T, Chen Q, Shimano K, Hanazawa R, [Hirakawa A](#), Yokota T, Hattori T. Circular walking is useful for assessing the risk of falls in early progressive supranuclear palsy. *Journal of Neurology*, 271(9):6349-6358. doi: 10.1007/s00415-024-12551-6. 2024
121. Yamaoka H, Hirai S, Hanazawa R, Yoshimura M, Hayashi T, Kaneoka A, Yamada K, Yoshino Y, Ebiko Y, Yamamura T, Ishikawa M, Sagawa H, Aoyama J, Fujii S, Fujita K, Kawano Y, [Hirakawa A](#), Sumita K. A thoracic CT imaging parameter predicting access difficulty in acute stroke thrombectomy. *Clinical Neurology and Neurosurgery*, 244:108453. doi: 10.1016/j.clineuro.2024.108453. 2024
122. Harada T, Kobayashi T, [Hirakawa A](#), Takayanagi T, Nogami M, Mochiyama T, Hirayama M, Foidart J-M, Osuga Y. Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study. *Fertility and Sterility*, S0015-0282(24)00604-6. doi: 10.1016/j.fertnstert.2024.07.011.2024
123. Nishikawa T, Kakunaga S, Tamura K, Ando M, Ozaki T, Kawai A, Ueda T, Kawasaki M, Tomatsuri S, Okamura N, Kamikura M, Hamada A, Yoshida A, [Hirakawa A](#), Shibata T, Nakamura K, Yonemori K. Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR TRIAL, NCCH1510). *Cancer*, doi: 10.1002/cncr.35483. 2024
124. Hirai S, Hanazawa R, Yoshimura M, Shigeta K, Sato Y, Taira N, Kawano Y, Karakama J, Obata Y, Hara M, Yamada K, Ishii Y, Sawada K, Imae S, Wakabayashi H, Sagawa H, Fujita K, Fujii S, Takahashi S, [Hirakawa A](#), Nemto S, Sumita K. Safety and Efficacy of Management for Intraprocedural Rupture During Endovascular Treatment for Intracranial Aneurysms. *Neurosurgery*, doi: 10.1227/neu.0000000000003126. 2024
125. Fujimaru T, Mori T, Sekine A, Chiga M, Mandai S, Kikuchi H, Mori Y, Hara Y, Fujiki T, Ando F, Susa K, Imori S, Naito S, Hanazawa R, [Hirakawa A](#), Mochizuki T, Suwabe T, Ubara Y,

- Uchida S, Sohara E. Importance of IFT140 in Patients with Polycystic Kidney Disease Without a Family History. *Kidney International Reports*, 9(9):2685-2694. doi: 10.1016/j.ekir.2024.06.021.2024
126. Arai S, Hanaoka M, Yamauchi S, Baba H, Hanazawa R, Sato H, Hirakawa A, Tokunaga M, Kinugasa Y. Modified oral antibiotics and mechanical bowel preparation (OAMBP) versus conventional OAMBP for sigmoid colon and rectal surgery: A multicenter randomized non-inferiority trial. *Annals of Gastroenterological Surgery*, doi/10.1002/ags3.12837, 2024
127. Takahashi Y, Kobori A, Hiroshima K, Sakamoto Y, Kimura M, Inaba O, Tanimoto K, Hanazawa R, Hirakawa A, Goya M, Sasano T. Mapping-Guided Ablation for Persistent Atrial Fibrillation (MAP-AF): A Multicenter, Single-blind, Randomized Controlled Trial. *Circulation: Arrhythmia and Electrophysiology*,17(8):e012829. doi: 10.1161/CIRCEP.124.012829.2024
128. Yatabe Y, Hanaoka M, Hanazawa R, Hirakawa A, Mukai T, Kimura K, Yamanoi K, Kono J, Yokota M, Takahashi H, Kobayashi A, Kobayashi K, Ichikawa N, Yasui M, Nakane K, Yamamoto M, Takenaka A, Nakamura Y, Takemasa I, Yabusaki N, Akamoto S, Tatarano S, MUurata K, Manabe T, Fujimura T, Kawamura M, Egi H, Yamaguchi S, Terai Y, Inoue S, Ito A, Kinugawa Y. Robotic versus open and laparoscopic pelvic exenterations for pelvic cancer: A multicenter propensity-matched analysis in Japan. *Surgical Endoscopy*, doi: 10.1007/s00464-024-10966-w, 2024
129. Suzuki N, Eguchi Y, Hirai T, Takahashi T, Takahashi Y, Watanabe K, Banno T, Sakaki K, Maki S, Takano Y, Taniguchi Y, Aoki Y, Konishi T, Hiraizumi Y, Yamagata M, Hirakawa A, Ohtori S. Outcome of intradiscal condoliase injection therapy for patients with recurrent lumbar disc herniation. *Asian Spine Journal*, 18(4):550-559. doi: 10.31616/asj.2024.0042. 2024
130. Ito S, Kinugasa Y, Yamauchi S, Sato H, Hirakawa A, Ishihara S, Shiomi A, Kanemitsu Y, Suto T, Takahashi H, Itabashi M, Shiozawa M, Hiyoshi M, Kobatake T, Komori K, Egi H, Ozawa H, Yamaguchi T, Inada R, Ito M, Hirano Y, Furutani A, Tanabe Y, Ueno H, Ohue M, Hida K, Kawai K, Sunami E, Ishida H, Uehara K, Watanabe J, Hotchi M, Ishibe A, Takii Y, Hiro J, Numata M, Takemasa I, Kato T, Kakeji Y, Hirata A, Ajioka Y. Long-term outcome after surgical resection of paraaortic lymph node metastasis of colorectal cancer: A multicenter retrospective study. *Dis Colon Rectum*, doi: 10.1097/DCR.0000000000003347.2024
131. Sakurai T, Sugimoto T, Akatsu H, Doi T, Fujiwara Y, Hirakawa A, Kinoshita F, Kuzuya M, Lee S, Matsumoto N, Matsuo K, Michikawa M, Nakamura A, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Suzuki H, Takechi H, Takeda S, Uchida K, Umegaki H, Wakayama S, Arai H, J-MINT study group. Japan-Multimodal intervention Trial for prevention of Dementia: a randomized controlled trial. *Alzheimer's & Dementia*, 20(6):3918-3930, doi: 10.1002/alz.13838. 2024

132. Yamada T, Minami T, Yoshino S, Emoto K, Mabuchi S, Hanazawa R, [Hirakawa A](#), Hashimoto M. Relationship Between Diaphragm Thickness, Thickening Fraction, Dome Excursion, and Respiratory Pressures in Healthy Subjects: an Ultrasound Study. *Lung*, 202(2):171-178. doi: 10.1007/s00408-024-00686-2, 2024
133. Kato M, Shiota M, Kimura T, Hanazawa R, [Hirakawa A](#), Takamatsu D, Tashiro K, Matsui Y, Hashine K, Saito R, Yokomizo A, Yamamoto Y, Narita S, Hashimoto K, Matsumoto H, Akamatsu S, Nishiyama N, Eto M, Kitamura H, Tsuzuki T, Japanese Urological Oncology Group. Validation study on the 2mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort. *International Journal of Urology*, 31(6):662-669. doi: 10.1111/iju.15434, 2024
134. Kobayashi M, Niimi M, Katsuda H, Akahoshi K, Kinowaki Y, Sasaki M, [Hirakawa A](#), Tateishi U, Tanabe M, Okamoto R. Optimization of Endoscopic Ultrasound Characteristics in the Diagnosis of Malignant Intraductal Papillary Mucinous Neoplasm. *Pancreas*, 53(6):e521-e527. doi: 10.1097/MPA.0000000000002329, 2024
135. Mikamo H, Takahashi S, Yamagishi Y, [Hirakawa A](#), Harada T, Nagashima H, Noguchi C, Masuko K, Maekawa H, Kashii T, Ohbayashi H, Hosokawa S, Maejima K, Yamato M, Manosuthi W, Paiboonpol S, Suganami H, Tanigawa R, Kawamura H, IVERMILCO Study Group. Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand. *Journal of Infection and Chemotherapy*, 30(6):536-543. doi: 10.1016/j.jiac.2023.12.012, 2023
136. Fujita K, Sato Y, Hanazawa R, Sagawa H, Ishikawa M, Fujii S, Aoyama J, Hirai S, Yoshimura M, Yoshino Y, Kawano Y, Shigeta K, Taira N, Karakama J, Ishiwada T, Yamashina M, [Hirakawa A](#), Sumita K. Impact of cancer history on long-term outcome after elective neuro-endovascular treatment in patients 80 years or older: a retrospective multicenter observational study. *Geriatrics & Gerontology International*, 24(2):211-217. doi: 10.1111/ggi.14784, 2023
137. Yamada T, Minami T, Yoshino S, Emoto K, Mabuchi S, Hanazawa R, [Hirakawa A](#), Hashimoto M. Diaphragm Ultrasonography: Reference Values and Influencing Factors for Thickness, Thickening Fraction, and Excursion in the Seated Position. *Lung*, 202(1):83-90. doi: 10.1007/s00408-023-00662-2, 2023
138. Kobayashi D, Kodera Y, Fukushima R, Morita M, Fushida S, Yamashita N, Yoshikawa K, Ueda S, Yabusaki H, Kusumoto T, Arigami T, Hidemura A, Omori T, Yamaguchi H, Hirono Y, Tsuji Y, Moon J H, Tomita T, Inamura H, Nakanishi K, Shimizu D, [Hirakawa A](#), Ishigami H, Kitayama j. Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer

- with Peritoneal Metastasis. *Annals of Surgical Oncology*, 31(2):735-743. doi: 10.1245/s10434-023-14240-6, 2023
139. Wen S, Unuma K, Hanazawa R, Nagano S, Watanabe R, Hirakawa A, Uemura K. Alcohol and Toxicological Factors Influencing Fatal Falls from Height in the Greater Tokyo Area: A Retrospective Study. *International Journal of Legal Medicine*, 138(3):793-800. doi: 10.1007/s00414-023-03125-8, 2023
140. Komatsuzaki K, Kageshima H, Sekino Y, Suzuki Y, Ugajin T, Tamaoka M, Hanazawa R, Hirakawa A, Miyazaki Y. Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans. *Allergology International*, 73(2)290-301. <https://doi.org/10.1016/j.alit.2023.10.007>, 2023
141. Mitsui T, Bando Y K, Hirakawa A, Furusawa K, Morimoto R, Taguchi E, Kimura A, Kamiya H, Nishikimi N, Komori K, Nishigami K, Murohara T. Role of Common Antihypertensives in the Growth of Abdominal Aortic Aneurysm at the Presurgical Stage. *Circulation Journal*, 17;5(11):405-414. doi: 10.1253/circrep.CR-23-0071, 2023
142. Shigeta T, Miyazaki S, Inaba O, Inamura Y, Nitta J, Sekiguchi Y, Takahashi A, Hachiya H, Nagata Y, Yamauchi Y, Hayashi T, Iwai S, Mizukami A, Ono Y, Handa K, Suzuki M, Suzuki A, Nakajima J, Hirao K, Okada H, Negishi M, Ikenouchi T, Yamamoto T, Goto K, Nishimura T, Tao S, Takigawa M, Hirakawa A, Goya M, Sasano T. Adjunctive posterior wall isolation for the treatment of persistent and longstanding persistent atrial fibrillation (CORNERSTONE AF) trial: Design and rationale. *Clinical Cardiology*, 47(1):e24164. doi: 10.1002/clc.24164, 2023
143. Niizuma K, Osawa S, Endo H, Izumi S, Ataka K, Hirakawa A, Iwano M, Tominaga T. Randomized Placebo-Controlled Trial of CL2020, an Allogenic Muse Cell-Based Product, in Subacute Ischemic Stroke, *Journal of Cerebral Blood Flow & Metabolism*, 43(12):2029-2039. doi: 10.1177/0271678X231202594,2023
144. Okuma H, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, Ariyama H, Kanai M, Kamikura M, Anjo K, Hiramatsu A, Sekine S, Okita N, Mano H, Nishikawa H, Nakamura K, Yonemori K. Phase 2 trial of nivolumab in metastatic rare cancer with dMMR or MSI-H and relation with immune phenotypic analysis (the ROCK trial). *Clinical Cancer Research*, 15;29(24):5079-5086, doi: 10.1158/1078-0432.CCR-23-1807, 2023
145. Kinoshita F, Yoshida K, Fujitani M, Imai Y, Kobayashi Y, Ito T, Okumura Y, Sato H, Mikami T, Jung S, Hirakawa A, Nakatochi M. Lifestyle parameters of Japanese agricultural and non-agricultural workers aged 60 years or older and less than 60 years: A cross-sectional observational study. *PLOS One*, 18(10):e0290662. doi: 10.1371/journal.pone.0290662, 2023
146. Mori M, Yoshizaki K, Watabe S, Ishige M, Hinoki A, Kondo T, Taguchi T, Hasegawa H, Hatata

- T, Tanuma N, Kirino N, [Hirakawa A](#), Naruto T, Imai M, Koike R, Hosoi K, Kusuda S. Safety, efficacy and pharmacokinetics of Palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: A multicenter phase II clinical trial. *The Lancet Regional Health - Western Pacific*, 39:100847. doi: 10.1016/j.lanwpc.2023.100847, 2023
147. Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study. *Cancer Discovery*, 13(8): 1814-1825, doi: 10.1158/2159-8290, 2023.
148. Yamaguchi Y, Tanaka H, Kimura K, Fukuda S, Fukushima H, Waseda Y, Yoshida S, Yokoyama M, [Hirakawa A](#), Tateishi U, Campbell S C, Fujii Y. Prognostic impact of the radiological infiltrative feature of primary renal tumor in metastatic renal cell carcinoma. *International Journal of Urology*. 30(10):913-921, doi: 10.1111/iju.15234, 2023, (2.600)
149. Hirai S, Hirakawa A, Fujita K, Ishiwada T, Sasaki M, Yoshimura M, Shigeta K, Sato Y, Yamada K, Ishikawa M, Sagawa H, Aoyama J, Fujii S, Ishii Y, Sawada K, Obata Y, Karakama J, Hara M, Kawano Y, Nemoto S, Sumita K. Imaging predictors of clinical outcomes after endovascular treatment in MRI-selected patients with acute basilar artery occlusion. *Clinical Neurology and Neurosurgery*, 231:107824, doi: 10.1016/j.clineuro.2023.107824. 2023
150. Yokoi A, Ukai M, Yasui T, Inokuma Y, Kim H D, Matsuzaki J, Yoshida K, Kitagawa M, Chattrairat K, Iida M, Shimada T, Manabe Y, Chang I Y, Asano-Inami E, Koya Y, Nawa A, Nakamura K, Kiyono T, Kato T, [Hirakawa A](#), Yoshida Y, Ochiya T, Hasegawa T, Baba Y, Yamamoto Y, Kajiyama H. Identifying high-grade serous ovarian carcinoma-specific extracellular vesicles by polyketone-coated nanowires. *Science Advances*, 9(27): eade6958 doi: 10.1126/sciadv.ade6958. 2023
151. Nakamura R, Tohnai G, Nakatochi M, Atsuta N, Watanabe H, Ito D, Katsuno M, [Hirakawa A](#), Izumi Y, Morita M, Hirayama T, Kano O, Kanai K, Hattori N, Taniguchi A, Suzuki N, Aoki M, Iwata I, Yabe I, Shibuya K, Kuwabara S, Oda M, Hashimoto R, Aiba I, Ishihara T, Onodera O, Yamashita T, Abe K, Mizoguchi K, Shimizu T, Ikeda Y, Yokota T, Hasegawa K, Tanaka F, Nakashima K, Kaji R, Niwa J, Doyu M, Terao C, Ikegawa S, Fujimori K, Nakamura S, Ozawa F, Morimoto S, Onodera K, Ito T, Okada Y, Okano H, Sobue G, on behalf of the Japanese Consortium for Amyotrophic Lateral Sclerosis research (JaCALS) study group. Genetic factors affecting survival in Japanese patients with sporadic amyotrophic lateral sclerosis: a genome-wide association study and verification in iPSC-derived motor neurons from patients. *Journal of Neurology, Neurosurgery & Psychiatry*, 94(10):816-824, doi. org/ 10. 1136/ jnnp- 2022-330851. 2023

152. Hosoya T, Oba S, Komiya Y, Kawata D, Kamiya M, Iwai H, Miyamoto S, Kataoka M, Tobiume M, Kanno T, Ainai A, Sato H, Hirakawa A, Mitui Y, Satoh T, Wakabayashi K, Yamada T, Otomo Y, Miyazaki Y, Hasegawa H, Suzuki T, Yasuda S. Apple-shaped obesity; a risky soil for cytokine-accelerated severity in COVID-19. *Proc Natl Acad Sci USA*, 30;120(22): e2300155120 doi: 10.1073/pnas.2300155120. 2023
153. Unuma K, Sato H, Wen S, Makino Y, Hirakawa A, Uemura K. The proportion of false-positives in positive Seratec® prostate-specific antigen SemiQuant test results in postmortem screening for seminal fluid. *Legal Medicine*. 62;102243. doi: 10.1016/j.legalmed.2023.102243. 2023
154. Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, Komai Y, Numao N, Yuasa T, Inoue M, Ushijima H, Kudo S, Shimano Y, Nakamura Y, Uchida Y, Uehara S, Tanaka H, Yaegashi H, Izumi K, Yokoyama M, Matsuoka Y, Yoshioka Y, Konishi K, Nakanishi K, Nagahara A, Hirakawa A, Koike R, Koga F, Nishimura K, Mizokami A, Yonese J, Kageyama Y, Yoshimura R, Fujii Y. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). *BMC Urology*. 23(1):33, doi: 10.1186/s12894-023-01202-z. 2023
155. Ohara M, Hirata K, Hallett M, Matsubayashi T, Chen Q, Kina S, Shimano K, Hirakawa A, Yokota T, Hattori T. Long term levodopa ameliorates sequence effect in simple, but not complex walking in early Parkinson's disease patients. *Parkinsonism & Related Disorders*. 108:105322 doi: 10.1016/j.parkreldis.2023.105322. 2023
156. Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Okubo M, Kamiya H, Hirakawa A, Kawasaki M, Kondo T, Suzuki T, Matsuo H. Diagnostic Accuracy of Artificial Intelligence-Based Angiography-Derived Fractional Flow Reserve Using Pressure Wire-Based Fractional Flow Reserve as Reference. *Circulation Journal*. 87(6): 783-790. doi: 10.1253/circj.CJ-22-0771. 2023
157. Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. *Journal of Clinical Oncology*, 41(15):2789-2799, doi: 10.1200/JCO.22.02558. 2023
158. Hattori T, Ohara M, Yuasa T, Azuma R, Chen Q, Hanazawa R, Hirakawa A, Orimo S, Yokota T. Callosal angle at splenium correlates with gait and cognition in normal pressure hydrocephalus. *Journal of Neurosurgery*. 139(2):481-491. doi: 10.3171/2022.12.JNS221825. 2023

159. Shitara K, Kawazoe A, Hirakawa A, Nakanishi Y, Furuki S, Fukuda M, Ueno Y, Raizer J, Arozullah A. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma. *Cancer Science*. 114(4):1606-1615. doi: 10.1111/cas.15684. 2023
160. Takenaka K, Kitazume Y, Kawamoto A, Fujii T, Udagawa Y, Watanabe R, Shimizu H, Hibiya S, Nagahori M, Ohtsuka K, Sato H, Hirakawa A, Watanabe M, Okamoto R. Serum Leucine-Rich  $\alpha 2$  Glycoprotein: A Novel Biomarker For Transmural Inflammation in Crohn's Disease. *American Journal of Gastroenterology*. 118(6):1028-1035. doi: 10.14309/ajg.0000000000002127. 2023
161. Inagaki T, Hashizume A, Hijikata Y, Yamada S, Ito D, Kishimoto Y, Torii R, Sato H, Hirakawa A, Katsuno M. Development of a functional composite for the evaluation of spinal and bulbar muscular atrophy. *Scientific Reports*. 12(1):17443. doi: 10.1038/s41598-022-22322-w. 2022
162. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kishimoto Y, Kinoshita F, Hirakawa A, Shimizu S, Nakamura T, Katsuno M. Mexiletine in Spinal and Bulbar Muscular Atrophy: A Randomized Controlled Trial. *Annals of Clinical and Translational Neurology*. 9(11):1702-1714. doi: 10.1002/acn3.51667. 2022
163. Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Fujiwara Y. Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. *Front Oncol*. 11:732525, doi: 10.3389/fonc.2021.732525. 2021
164. Sakaki K, Yoshii T, Arai Y, Torigoe I, Tomori M, Onuma H, Ogawa T, Hirakawa A, Sakai K, Okawa A. Effectiveness of Lumbosacral Orthosis after Discectomy for Lumbar Disc Herniation: A Prospective Comparative Study. *Spine*, 48(1):15-20, doi:10.1097/BRS.0000000000004475,2022
165. Kotani T, Imai K, Ushida T, Moriyama Y, Nakano-Kobayashi T, Osuka S, Tsuda H, Sumigama S, Yamamoto E, Kinoshita F, Hirakawa A, Iwase A, Kikkawa F, Kajiyama H. Pregnancy Outcomes in Women with Thyroid Diseases. *JMA journal*. 5(2):216-223, doi: 10.31662/jmaj.2021-0191, 2022
166. Oda G, Nakagawa T, Mori H, Onishi I, Fujioka T, Mori M, Kubota K, Hanazawa R, Hirakawa A, Ishikawa T, Okamoto K, Uetake H. Factors predicting upstaging from clinical N0 to pN2a/N3a in breast cancer patients. *World Journal of Clinical Oncology*, 13(9):748-757,doi:10.5306/wjco.v13.i9.748, 2022
167. Takahashi Y, Yamamoto T, Oyama J, Sugihara G, Shirai Y, Tao S, Takigawa M, Sato H, Sasaki M, Hirakawa A, Takahashi H, Goya M, Sasano T. Increase in Cerebral Blood Flow after Catheter Ablation of Atrial Fibrillation. *JACC: Clinical*

*Electrophysiology*, 8 (11) 1369-1377, doi:10.1016/j.jacep.2022.07.011, 2022

168. Murata K, Takahashi Y, Inaba O, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Sato H, Hanazawa R, Hirakawa A, Goya M, Sasano T. Efficacy of Left Atrial Posterior Wall Isolation Guided by Lesion Size Prediction Module for Non-paroxysmal Atrial Fibrillation. *EP Europace*, euac079, (2022) 00 1 - 8, doi: 10.1093/europace/euac079, 2022.
169. Nakayama K, Shachar S, Finn E H, Sato H, Hirakawa A, Misteli T. Large-scale mapping of positional changes of hypoxia-responsive genes upon activation. *Molecular Biology of the Cell*, 33(8): ar72. doi: 10.1091/mbc.E21-11-0593, 2022
170. Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M, Mizuno M, Hirakawa A, Hayakawa M, Sato Y. Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial. *BMJ OPEN*, 12(4): e057073, doi: 10.1136/bmjopen-2021-057073, 2022
171. Inose H, Kato T, Sasaki M, Matsukura T, Sasaki M, Matsukura Y, Hirai T, Yoshii T, Kawabata S, Hirakawa A, Okawa A. Comparison of decompression, decompression plus fusion, and decompression plus stabilization: a long-term follow-up of a prospective, randomized study. *The Spine Journal*, 22(5)747-755. doi: 10.1016/j.spinee.2021.12.014, 2021
172. Takino K, Kameshima M, Asai C, Kawamura I, Tomita S, Sato H, Hirakawa A, Yamada S. Neuromuscular electrical stimulation mitigates muscle weakness in elderly diabetic patients after cardiovascular surgery, *Annals of Physical and Rehabilitation Medicine*, 7;101659, doi: 10.1016/j.rehab.2022.101659, 2022
173. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, Kamiya M, Yamamoto A, Ando T, Shimada S, Shirai T, Okamoto T, Tateishi T, Endo A, Aiboshi J, Nosaka N, Yamanouchi H, Ugawa T, Nagaoka E, Oi K, Tao S, Maejima Y, Tanaka Y, Tanimoto K, Takeuchi H, Tohda S, Hirakawa A, Sasano T, Arai H, Otomo Y, Miyazaki Y, Yasuda S. Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. *Frontiers in Cardiovascular Medicine*, 19:8:767074, doi: 10.3389/fcvm.2021.767074, 2021
174. Noda-Narita S, Kawachi A, Okuyama A, Sadachi R, Hirakawa A, Goto Y, Fujiwara Y, Higashi T, Yonemori K. First-line treatment for lung cancer among Japanese older patients: a real-world analysis of hospital-based cancer registry data. *PLOS ONE*, 16(9): e0257489. doi: 10.1371/journal.pone.0257489, 2021
175. Yamada S, Hashizume A, Hijikata Y, Ito D, Kishimoto Y, Iida M, Koike H, Hirakawa A, Katsuno M. Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery & Psychiatry*, 92(10):1072-1079, doi: 10.1136/jnnp-2020-324615, 2021

176. Ezaki A, [Hirakawa A](#), Hanaoka H, Uyama Y. Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis. *Therapeutic innovation & regulatory science*, 55(5):1075-1081, doi: 10.1007/s43441-021-00309-5, 2021,
177. Sugimoto T, Sakurai T, Akatsu H, Doi T, Fujiwara Y, [Hirakawa A](#), Kinoshita F, Kuzuya M, Lee S, Matsuo K, Michikawa M, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Takechi H, Takeda S, Umegaki H, Wakayama S, Arai H, J-MINT investigators. The Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT): The Study Protocol for an 18-Month, Multicenter, Randomized, Controlled Trial. *The Journal of Prevention of Alzheimer's Disease*. 8(4):465-476, doi:10.14283/jpad.2021.29,2021.
178. Takahashi Y, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Inaba O, Murata K, Sasaki Y, Yoshimoto D, Kaneko M, Tanimoto Y, Isogai R, Yamashita S, Sato H, Hanazawa R, [Hirakawa A](#), Goya M, Sasano T. Alcohol Consumption Reduction and Clinical Outcomes of Catheter Ablation for Atrial Fibrillation. *Circulation: Arrhythmia and electrophysiology*, 14(6):e009770. doi:10.1161/circep.121.009770, 2021
179. Omori H, Hara M, Sobue Y, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Ota H, Okubo M, [Hirakawa A](#), Suzuki T, Kondo T, Leipsic J, Nørgaard B L, Matsuo H. Determination of the Optimal Measurement Point for Fractional Flow Reserve Derived From CTA Using Pressure Wire Assessment as Reference. *American Journal of Roentgenology*, 216:1492-1499 doi: 10.2214/AJR.20.24090,2021
180. Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, [Hirakawa A](#), Koike R, Kusuda S. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. *BMC Pediatrics*, 21(1):106. doi: 10.1186/s12887-021-02567-6,2021
181. Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Kawamura I, Okubo M, Kamiya H, Hirakawa A, Kawasaki M, Nakagawa M, Tsuchiya K, Suzuki Y, Ito T, Terashima M, Kondo T, Suzuki T, Escaned J, Matsuo H. Comparisons of Nonhyperemic Pressure Ratios: Predicting Functional Results of Coronary Revascularization Using Longitudinal Vessel Interrogation. *JACC. Cardiovascular interventions*, 13(22):2688-2698. doi: 10.1016/j.jcin.2020.06.060,2020
182. Ushida T, Kotani T, Hayakawa M, Hirakawa A, Sadachi R, Nakamura N, Moriyama Y, Imai K, Nakano-Kobayashi T, Kikkawa F. Antenatal corticosteroids and preterm offspring outcomes in hypertensive disorders of pregnancy: A Japanese cohort study. *Scientific reports*, 10(1):9312. Doi: 10.1038/s41598-020-66242-z, 2020
183. Kimura K, Itoh Y, Okada T, Kubota S, Kawamura M, Nakahara R, Oie Y, Kozai Yuka, Takase

- Y, Tsuzuki H, Nishio N, Hiramatsu M, Fujimoto Y, Mizutani T, [Hirakawa A](#), Naganawa S. Study Protocol: Prospective study of concurrent chemoradiotherapy with S-1 and hypofractionated radiotherapy for outpatients with early glottic squamous cell carcinomas *Asian Pacific Journal of Cancer Prevention*, 19:1195-1999, 2018
184. Kato M, [Hirakawa A](#), Sato H, Hanazawa R, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Grade group 2 (10%  $\geq$  GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate. *International Journal of Clinical Oncology*, 2021, doi: 10.1007/s10147-020-01841-4.
185. Kato M, [Hirakawa A](#), Kobayashi Y, Yamamoto A, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer. *International Journal of Clinical Oncology*, 25(12):2130-2137. 2020.
186. Goto T, Murata M, Nishida T, Terakura S, Kamoshita S, Ishikawa Y, Ushijima Y, Adachi Y, Suzuki S, Kato K, [Hirakawa A](#), Nishiwaki S, Nishio N, Takahashi Y, Kodera Y, Matsushita T, Kiyoi H. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. *Stem cells translational medicine*. 10(4):542-553, doi: 10.1002/sctm.20-0381. 2021.
187. Yokoi K, Hattori M, Satake Y, Tanaka Y, Sato M, Hashizume A, Hori A, Kawashima M, [Hirakawa A](#), Watanabe H, Katsuno M. Longitudinal analysis of premotor anthropometric and serological markers of Parkinson's disease. *Scientific Reports*, 25;10(1):20524, 2020
188. Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito M A, [Hirakawa A](#), Kiyoi H, Matsumura I, Miyazaki Y, Japan Adult Leukemia Study Group. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: A phase 1/2 dose- escalation study by the Japan Adult Leukemia Study Group. *International Journal of Hematology*. 113(3):395-403, 2021. doi: 10.1007/s12185-020-03032-3.
189. Ikenouchi T, Inaba O, Takamiya T, Inamura Y, Sato A, Matsumura Y, Sato H, [Hirakawa A](#), Takahashi Y, Goya M, Sasano T, Nitta J. The impact of left atrium size on selection of the pulmonary vein isolation method for atrial fibrillation: Cryoballoon or radiofrequency catheter ablation. *American Heart Journal*, 231:82-92, 2021.
190. Kuwatsuka Y, Atsuta Y, [Hirakawa A](#), Uchida N, Inamoto Y, Najima Y, Ikegame K, Eto T, Ozawa Y, Ichinohe T, Inoue M, Kimura T, Okamoto S, Miyamura K, Fukuda T. Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection. *International Journal of Hematology*, 112(6):841-850, 2020.
191. Takahashi K, Ishibashi E, Kubo T, Harada Y, Hayashi H, Kano M, Shimizu Y, Shirota H, Mori

- Y, Muto M, Ishioka C, Dosaka-Akita H, Matsubara H, Nishihara H, Sueoka-Aragane N, Toyooka S, [Hirakawa A](#), Tateishi U, Miyake S, Ikeda S. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). *Medicine (Baltimore)*. 99(32):e21457, doi: 10.1097/MD.00000000000021457, 2020.
192. Kitase Y, Sato Y, Arai S, Onoda A, Ueda K, Go S, Mimatsu H, Jabary M, Suzuki T, Ito M, Saito A, [Hirakawa A](#), Mukai T, Nagamura-Inoue T, Takahashi Y, Tsuji M, Hayakawa M. Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells. *Frontiers in Cellular Neuroscience*. 14:212, doi: 10.3389/fncel.2020.00212, 2020.
193. Gotoh M, Shimizu S, Yamamoto T, Ishizuka O, Yamanishi T, Mizokami A, Narimoto K, Toriyama K, Kamei Y, Nakayama S, Kuwatsuka Y, Mizuno M, [Hirakawa A](#). Regenerative treatment for male stress urinary incontinence by periurethral injection of adipose-derived regenerative cells: Outcome of the ADRESU study. *International Journal of Urology*. 27(10):859-865, 2020.
194. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, Ae K, Toguchida J, Ozaki T, [Hirakawa A](#), Motoi T, Sakai T, Kobayashi E, Gokita T, Okamoto T, Matsunobu T, Shimizu K, Koike H. Risk Factors of Local Recurrence after Surgery in Extra-Abdominal Desmoid-Type Fibromatosis: A Multicenter Study in Japan. *Cancer Science*. 111(8):2935-2942, doi: 10.1111/cas.14528, 2020.
195. Ushida T, Kotani T, Sadachi R, [Hirakawa A](#), Hayakawa M, Moriyama Y, Imai K, Nakano-Kobayashi T, Kikkawa F. Antenatal Corticosteroids and Outcomes in Preterm Twins. *Obstetrics and Gynecology*. 135:1387-1397, doi: 10.1097/AOG.0000000000003881, 2020.
196. Majima S, Wakahara K, Nishio T, Nishio N, Teranishi M, Iwano S, [Hirakawa A](#), Hashimoto N, Sone M, Hasegawa Y. Bronchial wall thickening is associated with severity of chronic rhinosinusitis. *Respiratory Medicine*. 170:106024, doi: 10.1016/j.rmed.2020.106024, 2020.
197. Kawachi A, Yamashita S, Okochi-Takada E, [Hirakawa A](#), Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. *Breast Cancer Research and Treatment*. 181:323-329. doi: 10.1007/s10549-020-05647-w, 2020.
198. Kato T, Motoji Y, Tamaki M, Inagaki M, Tsunekawa T, [Hirakawa A](#), Okawa Y, Tomita S. Clinical benefits of fast-track rehabilitation program for patients with uncomplicated type B acute aortic dissection. *General Thoracic and Cardiovascular Surgery*. 68(11):1234-1239, 2020
199. Suzuki K, [Hirakawa A](#), Ihara R, Iwata A, Ishii K, Ikeuchi T, Chung-KaiSun, Donohue M, Iwatsubo T. Effect of apolipoprotein E  $\epsilon$ 4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical*

- Interventions*, 6(1):e12007, doi: 10.1002/trc2.12007, 2020.
200. Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA) *Journal of Bone and Mineral Metabolism*. 38(4):522-532, doi: 10.1007/s00774-020-01091-4, 2020.
201. Kawase Y, Omori H, Tanigaki T, Hirakawa A, Hirata T, Ota H, Kikuchi J, Sobue Y, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. In vivo validation of resting full-cycle ratio and diastolic pressure ratio - simultaneous measurement with instantaneous wave-free ratio. *Cardiovascular Intervention and Therapeutics*, doi: 10.1007/s12928-020-00648-4, 2020.
202. Hattori M, Tsuboi T, Yokoi K, Tanaka Y, Sato M, Suzuki K, Arahata Y, Hori A, Kawashima M, Hirakawa A, Washimi Y, Watanabe H, Katsuno M. Subjects at risk of Parkinson's disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study. *Journal of Neurology*, 267(5):1516-1526; doi: 10.1007/s00415-020-09714-6, 2020.
203. Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. MASTER KEY Project: Powering Clinical Development for Rare Cancers through a Platform Trial. *Clinical Pharmacology & Therapeutics*, 108(3):596-605, doi: 10.1002/cpt.1817, 2020.
204. Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M; Rovatirelin Study Group. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. *Journal of Neurology, Neurosurgery & Psychiatry*, 91:254-262; doi: 10.1136/jnnp-2019-322168, 2020.
205. Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. *Journal of Bone and Mineral Metabolism*, 38(4):511-521, 2020.
206. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Sano T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. *The Prostate*, 80:284-290; doi: 10.1002/pros.23942, 2020.
207. Sakakibara S, Hashimoto R, Katayama T, Kenjyo M, Yokokawa Y, Saito Y, Hirakawa A, Ito M, Nakamura T, Hara K, Hashizume A, Aiba I, Inukai A, Katsuno M. Longitudinal change of DAT SPECT in Parkinson's disease and multiple system atrophy. *Journal of Parkinson's Disease*. 10(1):123-130, doi: 10.3233/JPD-191710, 2020.
208. Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, Kishimoto Y, Moriyoshi H, Hirakawa A, Katsuno M. Elevated serum creatine kinase in the early stage of sporadic

- amyotrophic lateral sclerosis. *Journal of Neurology*, 266(12):2952-2961, 2019.
209. Hirata T, Tanigaki T, Kawase Y, [Hirakawa A](#), Omori H, Okamoto S, Ota H, Sobue Y, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Pijls NHJ, Matsuo H. Post-occlusion hyperemia for fractional flow reserve assessment and pull-back curve analysis. *Cardiovascular Intervention and Therapeutics*, 35(2):142-149, doi: 10.1007/s12928-019-00579-9, 2020.
210. Hashizume A, Katsuno M, Suzuki K, Banno H, Takeuchi Y, Kawashima M, Suga N, Mano T, Araki A, Hijikata Y, [Hirakawa A](#), Sobue G; JASMITT study group. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. *Journal of Neurology*, 266:1211-1221, 2019.
211. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, [Hirakawa A](#), Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. *Translational Psychiatry*, 9: 126, 2019.
212. Shimizu S, Tsuchiya S, [Hirakawa A](#), Kato K, Ando M, Mizuno M, Osugi M, Okabe K, Katagiri W, Hibi H.. Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol. *BMC Oral Health*, 19:69, 2019.
213. Kato M, [Hirakawa A](#), Kobayashi Y, Yamamoto A, Ishida R, Sano T, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. *Prostate*, doi:10.1002/pros.23818, 2019.
214. Takano N, Yamada S, [Hirakawa A](#), Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E, Yamaguchi J, Ishikawa T, Sonohara F, Suenaga M, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H, Fujii T, Kodera Y. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. *Nagoya Journal of Medical Science*, 81:233-239, 2019.
215. Yokoyama T, Miyahara R, Funasaka K, Furukawa K, Yamamura T, Ohno E, Nakamura M, Kawashima H, Watanabe O, Hirooka Y, [Hirakawa A](#), Goto H. The utility of ultrathin endoscopy with flexible spectral imaging color enhancement for early gastric cancer. *Nagoya Journal of Medical Science*, 81:241-248, 2019.
216. Taniguchi A, Kawada JI, Go K, Fujishiro N, Hosokawa Y, Maki Y, Sugiyama Y, Suzuki M, Tsuji T, Hoshino S, Muramatsu H, Kidokoro H, Kinoshita F, [Hirakawa A](#), Takahashi Y, Sato Y, Natsume J. Comparison of clinical characteristics of human metapneumovirus and respiratory syncytial virus infection in hospitalized young children. *Japanese Journal of Infectious Diseases*, 72: 237-242, 2019.

217. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, Yokoi D, Hirakawa A, Taniguchi A, Morita M, Mizoguchi K, Mochizuki H, Kimura K, Katsuno M, Sobue G. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. *Neurology*, 92: e1868-e1877, 2019.
218. Maeda T, Sato Y, Hirakawa A, Nakatochi M, Kinoshita F, Suzuki T, Ichimura S, Ito R, Kudo R, Suzuki M, Hoshino S, Sugiyama Y, Muramatsu H, Kidokoro H, Kawada JI, Takahashi Y. Design of a prospective multicenter randomized controlled trial evaluating the effects of gastric lavage on coffee-ground emesis in neonates: study protocol. *Nagoya Journal of Medical Science*, 81:227-232, 2019.
219. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. *European Journal of Cancer*, 109: 84-91, 2019.
220. Sato Y, Ueda K, Kondo T, Hattori T, Mikrogeorgiou A, Sugiyama Y, Suzuki T, Yamamoto M, Hirata H, Hirakawa A, Nakanishi K, Tsuji M, Hayakawa M. Administration of Bone Marrow-Derived Mononuclear Cells Contributed to the Reduction of Hypoxic-Ischemic Brain Injury in Neonatal Rats. *Frontiers in Neurology*, 9: 987, 2018.
221. Saji N, Sakurai T, Ito K, Tomimoto H, Kitagawa K, Miwa K, Tanaka Y, Kozaki K, Kario K, Eto M, Suzuki K, Shimizu A, Niida S, Hirakawa A, Toba K; Strawberry study investigators. Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study). *BMJ Open*, 8: e021759, 2018.
222. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kinoshita F, Nakatochi M, Kobayashi Y, Hirakawa A, Nakamura T, Katsuno M. Study protocol for the MEXiletine hydrochloride administration trial: A placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS). *BMJ Open*, 8: e023041, 2018.
223. Tsunekawa T, Sawada M, Kato T, Motoji Y, Kinoshita T, Hirakawa A, Okawa Y, Tomita S. The prevalence and distribution of occlusive lesions of the cerebral arteries in patients undergoing coronary artery bypass graft surgery; *Seminars in Thoracic and Cardiovascular Surgery*; 2018, 30(4):413-420.
224. Kawamura I, Kajiura R, Motoji Y, Okamoto S, Tanigaki T, Omori H, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Tsunekawa T, Kato T, Kawase Y, Okubo M, Kamiya H, Tsuchiya K, Tomita S, Hirakawa A, Kondo T, Suzuki T, Matsuo H. Diagnostic Performance of the Simultaneous Acquisition Rest 99mTc-Tetrofosmin/Stress 201Tl Dual Isotope Protocol with a

- Semiconductor Camera: Comparison with the Rest-Stress <sup>99m</sup>Tc-Tetrofosmin Protocol. *Circulation Journal*, 82: 2837-2844, 2018.
225. Kato M, [Hirakawa A](#), Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. Integrating Tertiary Gleason Pattern 5 into the ISUP Grading System Improves Prediction of Biochemical Recurrence in Radical Prostatectomy Patients. *Modern Pathology*, 32:122-127, 2019.
226. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, [Hirakawa A](#), Wakabayashi T. Comparative Prospective Study of Microvascular Anastomosis Training by Self-Learning or with Expert Instruction. *World Neurosurgery*, 118: e818-e824, 2018.
227. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, [Hirakawa A](#), Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The impact of fertility treatment on the neonatal respiratory outcomes and amniotic lamellar body counts in twin pregnancies. *Clinica Chimica Acta*, 484: 192-196, 2018.
228. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, [Hirakawa A](#), Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The rate of neonatal respiratory distress syndrome/transient tachypnea in the newborn and the amniotic lamellar body count in twin pregnancies compared with singleton pregnancies. *Clinica Chimica Acta*, 484: 293-297, 2018.
229. Tanaka R, Yonemori K, [Hirakawa A](#), Kinoshita F, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y. Anti-cancer agent-induced life-threatening skin toxicities: A database study of spontaneous reporting data. *The Oncologist*, 24: 266-272, 2019.
230. Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Shimada K, Ishikawa Y, Hayakawa F, Nishio N, Nishiwaki S, [Hirakawa A](#), Kato K, Takahashi Y, Kiyoi H. Phase I study of cord blood transplantation with intra-bone marrow injection of mesenchymal stem cells: A clinical study protocol. *Medicine*, 97(17): e0449, 2018.
231. Ohsawa Y, Hagiwara H, Nishimatsu SI, [Hirakawa A](#), Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. *Journal of Neurology, Neurosurgery, and Psychiatry*, pii: jnnp-2018-317964. doi: 10.1136/jnnp-2018-317964, 2018.
232. Imai K, Kotani T, Nakano T, Ushida T, [Hirakawa A](#), Kikkawa F. Maternal protein S activity is associated with massive hemorrhage during Caesarean section: Retrospective case-control study. *The Journal of Maternal-Fetal & Neonatal Medicine*, 28:1-5, 2018 Feb.
233. Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, [Hirakawa A](#), Ando M, Natsume J, Kojima S. Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: a non-inferiority randomized control trial.

- PLOS ONE*, 13(2):e0192688, 2018.
234. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, [Hirakawa A](#), Tateyama H, Yokoi K. Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group. *European Journal of Cardio-Thoracic Surgery*, 49: 574-579, 2016.
235. Kawase Y, Kawasaki M, Kikuchi J, Hirata T, Okamoto S, Tanigaki T, Omori H, Ota H, Okubo M, Kamiya H, [Hirakawa A](#), Matsuo H. Residual pressure gradient across the implanted stent: An important factor of post-PCI physiological results. *Journal of Cardiology*, 71(5):458-463, 2018 May.
236. Hijikata Y, Hashizume A, Yamada S, Inagaki T, Ito D, [Hirakawa A](#), Suzuki K, Atsuta N, Tsuboi T, Hattori M, Horii A, Banno H, Sobue G, Katsuno M. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. *Neurology*, 90(17): e1501-e1509, 2018.
237. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Ito D, [Hirakawa A](#), Kinoshita F, Gosho M, Sobue G. Treatment with creatine monohydrate in spinal and bulbar muscular atrophy: study protocol for a randomized, double-blind, placebo-controlled trial. *JMIR Research Protocol*, 7(3): e69, 2018.
238. Miyauchi R, Itoh Y, Kawamura M, [Hirakawa A](#), Shibata K, Kajiyama H, Nakahara R, Kubota S, Ito J, Okada T, Kikkawa F, Naganawa S. Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer. *Nagoya Journal of Medical Science*, 79(2):211-220. doi: 10.18999/nagjms.79.2.211, 2017 Feb.
239. Miyamoto K, Ohkawara B, Ito M, Masuda A, [Hirakawa A](#), Sakai T, Hiraiwa H, Hamada T, Ishiguro N, Ohno K. Fluoxetine ameliorates cartilage degradation in osteoarthritis by inhibiting Wnt/ $\beta$ -catenin signaling. *PLoS One*, 12: e0184388, 2017.
240. Sawamura A, Okumura T, [Hirakawa A](#), Ito M, Ozaki Y, Ohte N, Amano T, Murohara T; CHANGE PUMP Investigators. Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation - Insights From the CHANGE PUMP Study. *Circulation Journal*, doi: 10.1253/circj.CJ-17-0549, 2017.
241. Ozeki N, Fukui T, Kawaguchi K, Nakamura S, Hakiri S, Kato T, [Hirakawa A](#), Yokoi K. A survival analysis using physique-adjusted tumor size of non-small cell lung cancer. *International Journal of Clinical Oncology*, doi: 10.1007/s10147-017-1219-6, 2017.
242. Ogawa C, Kidokoro H, Fukasawa T, Yamamoto H, Ishihara N, Ito Y, Sakaguchi Y, Okai Y, Ohno A, Nakata T, Azuma Y, Hattori A, Kubota T, Tsuji T, [Hirakawa A](#), Kawai H, Natsume J. Cytotoxic edema at onset in West syndrome of unknown etiology: a longitudinal DTI study. *Epilepsia*, doi: 10.1111/epi.13988, 2018.

243. Kawase Y, Kawasaki M, Tanigaki T, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, [Hirakawa A](#), Suzuki T, Matsuo H. Postocclusion hyperemia for fractional flow reserve after percutaneous coronary intervention. *JACC-Cardiovascular Interventions*, 10. doi: 10.1161/CIRCINTERVENTIONS.117.005674, 2017.
244. Kato M, Kimura K, [Hirakawa A](#), Kobayashi Y, Ishida R, Kamihira O, Majima T, Funahashi Y1, Sassa N, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Prognostic parameter for high risk prostate cancer patients at initial presentation. *Prostate*, 78: 11-16, 2018.
245. Shimizu S, Yamamoto T, Nakayama S, [Hirakawa A](#), Kuwatsuka Y, Funahashi Y, Matsukawa Y, Takanari K, Toriyama K, Kamei Y, Narimoto K, Yamanishi T, Ishizuka O, Mizuno M, Gotoh M. Design of a single-arm clinical trial of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence in Japan: the ADRESU study protocol. *BMC Urology*, 17: 89, 2017.
246. Yokoi A, Yoshioka Y, [Hirakawa A](#), Yamamoto Y, Ishikawa M, Ikeda S, Kato T, Niimi K, Kajiyama H, Kikkawa F, Ochiya T. A combination of circulating miRNAs for the early detection of ovarian cancer. *Oncotarget*, 8: 89811-89823, 2017.
247. Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kuwahara T, Yamamura T, Funasaka K, Nakamura M, Miyahara R, Ishigami M, Watanabe O, Hashimoto S, [Hirakawa A](#), Ratanachu-ek T, Goto H. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination. *Endoscopy International Open*, 5: E1136-E1143, 2017.
248. Kawase Y, Tanigaki T, [Hirakawa A](#), Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. Frequency of a large drift caused by pressure wire using optical fibers. *Cardiovascular Intervention and Therapeutics*, doi: 10.1007/s12928-017-0481-x, 2017.
249. Hyodo R, Sato Y, Ito M, Sugiyama Y, Ogawa C, Kawai H, Nakane T, Saito A, [Hirakawa A](#), Kidokoro H, Natsume J, Hayakawa M. Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes. *Archives of Disease in Childhood*, doi: 10.1136/archdischild-2016-311403, 2017.
250. Hashizume A, Katsuno M, Suzuki K, [Hirakawa A](#), Hijikata Y, Yamada S, Inagataki T, Banno M, Sobue G. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy -Natural history-controlled study- *Journal of Neurology, Neurosurgery, and Psychiatry*, 88: 1026-1032, 2017.
251. Ozeki N, Kawaguchi K, Fukui T, Fukumoto K, Nakamura S, Hakiri S, Kato T, [Hirakawa A](#), Okasaka T, Yokoi K. The diffusing capacity of the lung for carbon monoxide is associated with the histopathological aggressiveness of lung adenocarcinoma, *European Journal of Cardio-Thoracic Surgery*, 52:969-974, doi:10.1093/ejcts/ezx124, 2017.

252. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, [Hirakawa A](#), Wakabayashi T. Hands-on simulation versus traditional video-learning in teaching microsurgery technique. *Neurologia Medico-Chirurgica*, 57:238-245, 2017.
253. Nakanishi K, Sato Y, Mizutani Y, Ito M, [Hirakawa A](#), Higashi Y. Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats. *Scientific Reports*, 7:44111, 2017.
254. Kato T, Tamaki M, Tsunekawa T, Motoji Y, [Hirakawa A](#), Okawa Y, Tomita S. Health-Related Quality of Life Prospectively Evaluated by the 8-item Short Form After Endovascular Repair Versus Open Surgery for Abdominal Aortic Aneurysms. *Heart Vessel*, doi: 10.1007/s00380-017-0956-9, 2017.
255. Imai K, Kotani T, Tsuda H, Nakano T, [Hirakawa A](#), Kikkawa F. A Novel Approach to Detecting Postpartum Hemorrhage Using Contrast-Enhanced Ultrasound. *Ultrasound in medicine and biology*, 43(3):615-620, 2017.
256. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Suzuki K, Kondo N, Kawai K, Noda S, Nakanishi H, Banno H, [Hirakawa A](#), Koike H, Halievski K, Jordan CL, Katsuno M, Sobue G. Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy. *PLoS One*, 11(12): e0168846, 2016.
257. Yamasaki S, [Hirakawa A](#), Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. *Annals of Hematology*, 96(2):289-297, 2017.
258. Kato T, Tsunekawa T, Motoji Y, [Hirakawa A](#), Okawa Y, Tomita S. The side-to-side fashion for individual distal coronary anastomosis using venous conduit. *Heart and Vessels*, 32(4):385-389, 2017.
259. Suzuki N, [Hirakawa A](#), Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. *Haemophilia*, 23(2):215-221, 2017.
260. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Iida M, Noda S, Nakanishi H, Banno H, Mano T, [Hirakawa A](#), Adachi H, Watanabe H, Yamamoto M, Sobue G. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. *Annals of Clinical and Translational Neurology*, 3: 537-546, 2016.
261. Atsuta Y, [Hirakawa A](#), Nakasone H, Kurosawa S, Oshima K, Sakai R, Ohashi K, Takahashi S, Mori T, Ozawa Y, Fukuda T, Kanamori H, Morishima Y, Kato K, Yabe H, Sakamaki H, Taniguchi S, Yamashita T. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, 22: 1702-1709, 2016.

262. Okuma H, Koizumi F, [Hirakawa A](#), Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. *British Journal of Cancer*, 115: 411-419, 2016.
263. Yokoi D, Atsuta N, Watanabe H, Nakamura R, [Hirakawa A](#), Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Kaji R, Sobue G; JaCALs. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. *Journal of Neurology*, 263: 1129-1136, 2016.
264. Harano K, [Hirakawa A](#), Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. *Gynecologic Oncology*, 141: 447-453, 2016.
265. Nagata T, Sobajima H, Ohashi N, [Hirakawa A](#), Katsuno T, Yasuda Y, Matsuo S, Tsuboi N, Maruyama S. Association between 24h Urinary Sodium and Potassium Excretion and Estimated Glomerular Filtration Rate (eGFR) Decline or Death in Patients with Diabetes Mellitus and eGFR More than 30 ml/min/1.73m<sup>2</sup>. *PLOS ONE*, 11: e0152306, 2016.
266. Yamada S, Fujii T, [Hirakawa A](#), Kanda M, Sugimoto H, Kodera Y. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. *Langenbeck's Archives of Surgery*. 401(8):1143-1152, 2016.
267. Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, [Hirakawa A](#), Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. *Leukemia*, 30: 1568-1579, 2016.
268. Tanaka R, Yonemori K, [Hirakawa A](#), Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents. *Oncologist*, 21: 508-513, 2016.
269. Kato M, Tsuzuki T, Kimura K, [Hirakawa A](#), Kinoshita F, Sassa N, Ishida R, Fukatsu A, Kimura T, Funahashi Y, Matsukawa Y, Hattori R, Gotoh M. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. *Modern Pathology*. 29: 166-73, 2016.
270. Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, [Hirakawa A](#), Gotoh M. The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia. *Urology*. 88: 149-154, 2016.
271. Imai K, Kotani T, Tsuda H, Mano Y, Nakano T, Ushida T, Li H, Miki R, Sumigama S, Iwase A,

- Hirakawa A, Ohno K, Toyokuni S, Takeuchi H, Mizuno T, Suzumura A, Kikkawa F. Neuroprotective potential of molecular hydrogen against perinatal brain injury via suppression of activated microglia. *Free Radical Biology & Medicine*, 91: 154-163, 2016.
272. O Watanabe H, Atsuta N, Hirakawa A (co-first author), Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, Watanabe H, Ito M, Katsuno M, Izumi Y, Morita M, Kanai K, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Kawata A, Aoki M, Tsuji S, Nakashima K, Kaji R, Sobue G. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. *Journal of Neurology, Neurosurgery, and Psychiatry*, 87: 851-858, 2016.
273. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Hirakawa A, Tateyama H, Yokoi K. Prognostic impact of tumour size in completely resected thymic epithelial tumours. *European Journal of Cardio-Thoracic Surgery*, 49: 574-579, 2016.
274. Harano K, Yonemori K, Hirakawa A. The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study. *Breast Cancer*, 23: 797-806, 2016.
275. Nakano T, Kotani T, Mano Y, Tsuda H, Imai K, Ushida T, Li H, Miki R, Sumigama S, Sato Y, Iwase A, Hirakawa A, Asai M, Toyokuni S, Kikkawa F. Maternal molecular hydrogen administration on lipopolysaccharide-induced mouse fetal brain injury. *Journal of Clinical Biochemistry and Nutrition*, 57: 178-182, 2015.
276. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. *International Journal of Clinical Oncology*, 21: 168-176, 2016.
277. Tsuda H, Hirakawa A, Kotani T, Sumigama S, Mano Y, Nakano T, Imai K, Kawabata I, Takahashi Y, Iwagaki S, Kikkawa F. Risk assessment for neonatal RDS/TTN using gestational age and the amniotic lamellar body count in twin pregnancies. *Clinica Chimica Acta*. 451: 301-304, 2015.
278. Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T. The features of clearance in recombinant factor IX (BeneFIX®). *Haemophilia*, 21: 702-707, 2015.
279. Nakamura S, Fukui T, Kawaguchi K, Fukumoto K, Hirakawa A, Yokoi K. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma? *Lung Cancer*, 89: 38-42, 2015.
280. Hashizume A, Katsuno M, Suzuki K, Banno H, Suga N, Mano T, Araki A, Hijikata Y, Grunseich C, Kokkinis A, Hirakawa A, Watanabe H, Yamamoto M, Fischbeck KH, Sobue G. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study, *Neuromuscular Disorders*, 25: 554-562, 2015.

281. Okada N, Tajima K, Takami Y, Kato W, Kei F, Hibino M, Munakata H, Sakai Y, [Hirakawa A](#), Usui A. Valve selection for the aortic position in dialysis patients. *The Annals of Thoracic Surgery*; 99: 1524-1531, 2015.
282. Hattori T, Sato Y, Kondo T, Ichinohashi Y, Sugiyama Y, Yamamoto M, Kotani T, Hirata H, [Hirakawa A](#), Suzuki S, Tsuji M, Ikeda T, Nakanishi K, Kojima S, Blomgren K, Hayakawa M. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats. *Developmental Neuroscience*, 37: 95-104, 2015.
283. Kato T, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, [Hirakawa A](#), Yokoi K. The contact length between the tumor contour and the lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma. *General Thoracic and Cardiovascular Surgery*, 63: 343-348, 2015.
284. Tsuda H, Kotani T, Sumigama S, Mano Y, Kawabata I, Takahashi Y, Iwagaki S, [Hirakawa A](#), Kikkawa F. Amniotic lamellar body count: predicting and distinguishing neonatal respiratory complications in twin pregnancies. *Clinica Chimica Acta*, 441: 75-78, 2015.
285. ○Watanabe H, Atsuta N, Nakamura R, [Hirakawa A \(co-first author\)](#), Watanabe H, Ito M, Senda J, Katsuno M, Izumi Y, Morita M, Tomiyama H, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Aoki M, Tsuji S, Nakano I, Kaji R, Sobue G. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, 16: 230-236, 2015.
286. Kataoka Y, Nishida S, [Hirakawa A](#), Oiso Y, Arima H. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus. *Endocrine Journal*, 62: 195-200, 2015.
287. Ozeki N, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, [Hirakawa A](#), Yokoi K. Therapeutic surgery without a definitive diagnosis can be an option in selected patients with suspected lung cancer. *Interactive Cardiovascular and Thoracic Surgery*, 5:830-837, 2014.
288. Taniyama TK, Hashimoto K, Katsumata, N, [Hirakawa A](#), Yonemori K, Yunokawa M, Shimizu C, Tamura K, Ando M, Fujiwara Y. Can oncologists predict survival for patients with progressive disease after standard chemotherapies? *Current Oncology*, 21: 84-90, 2014.
289. Harano K, [Hirakawa A](#), Kato T, Suzuki K, Watanabe S, Katsumata N. Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan. *Journal Gynecologic Oncology*, 25: 124-129, 2014.
290. Yamada S, [Hirakawa A](#). Reply to: appropriate statistical descriptions for evaluating the predictive role of epithelial-to-mesenchymal transition in patients with pancreatic cancer. *Surgery*, 155: 959-960, 2014.

291. Arima H, Wakabayashi T, Nagatani T, Fujii M, [Hirakawa A](#), Murase T, Yambe Y, Yamada T, Yamakawa F, Yamamori I, Yamaguchi M, Oiso Y. Adipsia increases risk of death in patients with central diabetes insipidus. *Endocrine Journal*, 61:143-148, 2014.
292. Goto M, Yamamoto T, Kato M, Majima T, Toriyama K, kamei Y, Matsukawa Y, [Hirakawa A](#), Funahashi Y. Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients. *International Journal of Urology*, 21: 294-300, 2014.
293. Ozeki N, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ito S, Sakao Y, Mitsudomi T, [Hirakawa A](#), Yokoi K. Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small cell lung cancer. *European Journal of Cardio-Thoracic Surgery*, 45: 687-692, 2014.
294. Asano J, [Hirakawa A](#), Hamada C, Yonemori K, Hirata T, Shimizu C, Tamura K, Fujiwara Y. Use of Cox's cure model to establish clinical determinants of long-term disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy. *International Journal of Breast Cancer*, 354579, 2013.
295. Nakamura S, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ishiguro F, [Hirakawa A](#), Yokoi K. Prognostic impact of tumor size eliminating the ground glass opacity component: modified clinical T descriptors of the TNM classification of lung cancer. *Journal of Thoracic Oncology*, 8: 1551-1557, 2013.
296. Nakamura R, Atsuta N, Watanabe H, [Hirakawa A](#), Watanabe H, Ito M, Senda J, Katsuno M, Tanaka F, Izumi Y, Morita M, Ogaki K, Taniguchi A, Aiba I, Mizoguchi K, Okamoto K, Hasegawa K, Aoki M, Kawata A, Abe K, Oda M, Konagaya M, Imai T, Nakagawa M, Tsuji S, Kaji R, Nakano I, Sobue G. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. *Journal of Neurology, Neurosurgery, and Psychiatry*, 84:1365-1371, 2013.
297. Hirano K, Ohgomori T, Kobayashi K, Tanaka F, Matsumoto T, Natori T, Matsuyama Y, Uchimura K, Sakamoto K, Takeuchi H, [Hirakawa A](#), Suzumura A, Sobue G, Ishiguro N, Imagama S, Kadomatsu K. Ablation of keratan sulfate accelerates early phase pathogenesis of ALS. *PLoS ONE*, 25: e66969, 2013.
298. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, [Hirakawa A](#), Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K. Minocycline selectively inhibits M1 polarization of microglia. *Cell Death & Disease*, 7: e525, 2013.
299. Sato Y, Kawataki M, [Hirakawa A](#), Kato T, Itani T, Hayakawa M. The diameter of the inferior vena cava provides a noninvasive way of calculating central venous pressure in neonates. *Acta Paediatrica*, 102: e241-e246, 2013.
300. Tanabe Y, Hashimoto K, Shimizu C, [Hirakawa A](#), Harano K, Yunokawa M, Yonemori K,

- Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. *International Journal of Clinical Oncology*, 18: 132-138, 2013.
301. Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Fujiwara Y, Saito Y, Yamamoto H. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. *Biological & Pharmaceutical Bulletin*, 35: 717-724, 2012.
302. Kojima Y, Hashimoto K, Ando M, Hirakawa A, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Hosono A, Makimoto A, Fujiwara Y. Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. *Journal of Cancer Research and Clinical Oncology*, 138: 1249-1257, 2012.
303. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yasuhiro F. Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal. *PLoS ONE*, 7: e44393, 2012.
304. Yonemori K, Hirakawa A, Ryushima Y, Saito M, Yamamoto H, Hirata T, Ando M, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Yamamoto H, Fujiwara. An analysis of guidance for proper usage documents for oncology drugs in Japan. *Pharmaceutical Medicine*, 26: 165-170, 2012.
305. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Furuta K, Tsuda H, Fujiwara Y. Immunohistochemical profile for unknown primary adenocarcinoma. *PLoS ONE*, 7: e31181, 2012.
306. Hashimoto K, Yonemori K, Katsumata N, Hirakawa A, Hirata T, Yamamoto H, Shimizu C, Tamura K, Ando M, Fujiwara Y. Use of squamous cell carcinoma antigen as biomarker of chemotherapy response in patients with metastatic cervical carcinoma. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 159: 394-398, 2011.
307. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. The notorious "drug lag" for oncology in Japan. *Investigational New Drugs*, 29: 706-712, 2011.
308. Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Do investigators show selection biases when enrolling patients in phase I oncology registration trials? *Journal of Geriatric Oncology*, 2: 25-30, 2011.
309. Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Compliance with good clinical practice in oncology registration trials in Japan. *Annals of Oncology*, 22: 1451-1456, 2011.
310. Hirata T, Yonemori K, Hirakawa A, Shimizu C, Tamura K, Ando M, Katsumata N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients.

- European Respiratory Journal*, 38: 1425-1430, 2011.
311. Hirata T, Yonemori K, Ando M, Hirakawa A, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. Efficacy of taxane regimens in patients with metastatic angiosarcoma. *European Journal of Dermatology*, 21: 539-545, 2011.
312. Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y, Hasegawa T. Contrasting prognostic implications of platelet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. *Annals of Surgical Oncology*, 18: 2841-2850, 2011.
313. Hashimoto K, Yonemori K, Shimizu C, Hirakawa A, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Ando M, Fujiwara Y. A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. *Medical Oncology*, 28: 434-440, 2011.
314. Hashimoto K, Yonemori K, Katsumata N, Shimizu C, Hirakawa A, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. *Annals of Oncology*, 21: 2195-2200, 2010.
315. Yonemori K, Hirakawa A, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S. Participation of elderly patients in registration trials for oncology drug applications in Japan. *Annals of Oncology*, 21: 2112-2118, 2010.
316. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. *Journal of Surgical Oncology*, 101: 222-227, 2010.
317. Yonemori K, Kouno T, Ando M, Hirakawa A, Yamamoto H, Ono M, Hirata T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Influence of suboptimal treatment in patients with mediastinal primary non-seminomatous germ cell tumor. *Oncology*, 78: 34-39, 2010.
318. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita T, Shibui S, Fujiwara Y. Disruption of the blood brain barrier by brain metastases of triple negative and basal-type breast cancer but not HER2/neu-positive breast cancer. *Cancer*, 116: 302-308, 2010.
319. Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. *British Journal of Cancer*, 101: 1529-1536, 2009.
320. Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, Tamura K, Katsumata N, Hirakawa A, Matsumoto K, Yamanaka Y, Arioka H, Fujiwara Y. Irinotecan plus carboplatin for

patients with carcinoma of unknown primary site. *British Journal of Cancer*, 100: 50-55, 2008.